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Abstract
Chronic kidney disease (CKD), especially when requiring kidney replacement therapy
(hemodialysis (HD) and peritoneal dialysis (PD)), is associated with extracellular water expansion
with increased total body sodium. Sodium can also be accumulated in tissues independently of
extracellular water. Sodium-23 magnetic resonance imaging (23Na MRI) can quantify the
concentration of sodium nuclei in tissues. Applied to the human leg, quantification of tissue
sodium concentrations mainly at the skin and muscle level is possible. We hypothesized that
increased tissue sodium concentrations exert toxic effects in CKD and dialysis. We aimed to (1)
compare tissue sodium concentrations in adults, children and adolescents with CKD, HD and PD
against healthy individuals, (2) identify their predictors, (3) understand their connection to left
ventricular structure in patients receiving HD and (4) observe their relationship with adverse
cardiovascular events and mortality in patients receiving HD and PD. Tissue sodium
concentrations were increased in adult patients receiving HD and PD, with respect to healthy
individuals. In children and adolescents with CKD, tissue sodium concentrations varied depending
on CKD etiology, suggesting kidney disorders can be associated with either sodium wasting or
accumulation. Tissue sodium concentrations were associated with older age and overweight in
healthy individuals; in patients with CKD and receiving dialysis, hypoalbuminemia was an
important predictor of tissue sodium concentrations. In pediatric CKD, proteinuria was also
positively associated with tissue sodium concentrations, suggesting a role of proteinuria in
increased sodium reabsorption. In patients receiving HD, dialysate sodium concentration was
strongly positively associated with skin sodium concentrations.

ii

In patients receiving HD, tissue sodium concentrations were associated with left ventricular
hypertrophy and dilatation, with tissue sodium concentrations being highest in patients with a
dilated heart. Skin sodium concentration was associated with major cardiovascular adverse events
and mortality in patients receiving HD or PD. These findings expand our understanding on the
toxicity of sodium in CKD and point out critical issues of current dialysis treatment practices.
Future studies should explore improved technical applications of 23Na MRI and experiment with
new therapies and treatment strategies to reduce tissue sodium concentration in patients with CKD
and those receiving dialysis.
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Lay Summary
Sodium, one of the two constituents of table salt along with chloride, is the main ion contained in
extracellular water. One of the main functions of the kidneys is to control extracellular water
balance by excreting excess sodium and water. With sodium-23 magnetic resonance imaging (23Na
MRI) sodium concentration in human leg tissues can be measured. We hypothesized that diseased
kidneys, especially when kidney replacement therapy is necessary, are associated with increased
tissue sodium concentration. Our goals are to (1) compare tissue sodium concentrations in adults
and children with kidney disease and receiving dialysis against healthy individuals, (2) identify
what factors are associated with them, (3) understand their connection to heart structure in patients
receiving dialysis and (4) observe their relationship with heart disease such as myocardial
infarction and death in patients receiving dialysis.

In the first project, we found that adult patients receiving dialysis had higher tissue sodium
concentrations compared with healthy individuals. Tissue sodium concentrations were higher in
older, overweight individuals and when serum levels of the protein albumin were lower. In the
second project, we found that tissue sodium concentrations in children and adolescents with kidney
disease differed depending on what kind of kidney disease they had, suggesting that some forms
of kidney disease lose sodium though the urine, whereas others reabsorb too much sodium from
the urine. In the third project, we found that tissue sodium concentrations in patients receiving
hemodialysis were mirrored by alterations in the heart structure, such as ventricle dilatation and
increased wall thickness. In the fourth project, we observed that higher tissue sodium
concentrations in the skin of patients receiving dialysis was associated with more occurrences of
heart disease and death. We also found out that hemodialysis using high sodium concentration in
v

the dialysis fluid led to higher skin sodium concentration, suggesting hemodialysis itself may lead
to tissue sodium accumulation.

These findings suggest that tissue sodium in kidney disease and dialysis is toxic. These results
should prompt a change in dialysis prescriptions to reduce the amount of sodium accumulation,
and future studies should design new treatments using tissue sodium as a target.
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Chapter 1
1.1 Sodium and Compartment Physiology
Traditional physiology explains sodium balance in mammals and humans as essentially regulated
at two levels: (1) at a body compartment level, where sodium is tightly linked with water and
potassium, as a function of tissue composition and driving hydrostatic and osmotic forces,
regulating fluid shifts between body compartments; (2) at the kidney level, where a fraction of the
sodium contained in the blood plasma (intravascular compartment) is finally excreted from the
body, finely regulated by mechanisms of filtration, reabsorption and secretion. Other pathways of
sodium loss, via the gastrointestinal system and through sweating, are - from a physiological
standpoint – marginal and have been therefore omitted from discussion in this chapter. More
recently, a third level of sodium regulation has been described – accumulated in the dermal skin
layer without commensurate water, bound to negatively charged proteoglycans – as osmotically
inactive sodium.

1

Compartment physiology and the Starling Equation
Compartment physiology describes the distribution and behavior of fluids within the human body.
It is key to understanding the physiology of sodium, as the main extracellular ion, and its
relationship with the surrounding environment.

The human body is composed by 50 (in women) to 60% (in men) of water, with a physiological
decline with aging. Furthermore, visceral organs, brain, muscles and the skin consist of ~75%
water, as opposed to 10-20% in fat tissue and skeletal bones.1 According to compartment
physiology, total body water is divided into two compartments: the extracellular volume (ECV)
and the intracellular volume (ICV). The ECV is composed of five subcompartments: (1) the
intravascular (plasma) space, (2) the interstitial and lymph fluids, (3) connective tissue and bones,
(4) transcellular fluid (contained in cavities such as the pleural space, the peritoneal cavity, the
cerebrospinal fluid system), and (5) fat tissue (Figure 1.1).

2

Figure 1.1: Summary of water distribution within body compartments.

The ECV contains 45-48% of total body water in women, as opposed to 42-45% in men, who have
a larger ICV due to a greater muscle mass.1 The ICV constitutes 53-58% of total body water, with
almost 75% being represented by skeletal muscles (Figure 1.1). For this reason, loss of muscle
mass causes a redistribution of total body water from the ICV to the ECV.
Water movements between compartments are regulated by a balance of hydrostatic and osmotic
forces, according to the following formula:
Pic – Pec = Πic – Πec

3

Where P stands for the hydrostatic forces, Π for the osmotic forces, ic for intracellular and ec for
extracellular. In animal cells, the presence of a flexible cellular membrane (phospholipid bilayer)
causes the water shifts between the ECV and ICV to be mediated only by the balance of
extracellular and intracellular osmotic forces, as the extracellular and intracellular hydrostatic
forces cancel each other out at equilibrium. The osmotic movement of water across a
semipermeable membrane can be described by the following relationship:
Osmotic Water Flux ∝ Lp * Δ[c] * σ
Where Lp is the hydraulic permeability of the semipermeable membrane, Δ[c] the concentration
difference of the solute of interest at the two sides of the membrane and σ Staverman’s reflection
coefficient.
Briefly, σ describes the behavior of a solute, as the ratio of the observed difference in osmotic
pressure (ΔΠobs) at the two sides of the membrane and the ideal difference in osmotic pressure
(ΔΠideal) generated by an impermeable solute. Ranging from 0 to 1, when σ → 1, then the solute
is completely impermeable and generates maximum osmotic water flux; when σ → 0, then the
solute is maximally permeable, and no osmotic water flux is generated.
Based on their ability to generated osmotic water flux, solutes can be divided into ineffective
osmoles, i.e. solutes with a σ → 0 and/or not able to generate a concentration difference across a
given semipermeable membrane, and as such do not generate osmotic water flux, and effective
osmoles, i.e. molecules with a σ > 0 and generate a concentration difference across the
semipermeable membrane, and are able to generate osmotic water flux.
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Fluid Balance between the Extracellular and Intracellular Compartments
Key concepts in understanding compartment physiology pertain to solute and water distribution
between the ECV and the ICV, and within the ECV subcompartments, mainly between the vascular
space and the interstitium.

Fluids in the ECV and ICV compartments are in a dynamic balance: the ICV is rich in fixed anions,
such as adenosine tri-phosphate (ATP), phospho-creatine and sulfate anion. In order to maintain
electroneutrality, these negative charges attract the two main body cations – sodium and potassium
– with accompanying osmotic water influx, as the cellular membrane is permeable to both sodium
and potassium. Without intervention, these two ions would enter the intracellular space, causing
the cell to swell and burst from the osmotic water influx. To prevent this from happening, the
relative distribution of sodium and potassium is highly regulated by a membrane protein, the
sodium/potassium (Na+/K+) ATPase. This protein extrudes three sodium ions from the cell and
imports two potassium ions into the cell, so that in practice, an osmotic gradient in sodium and
potassium is generated and these two ions become effective osmoles. As a consequence, 95% of
total body sodium has been estimated to be distributed in the ECV and 98% of total body potassium
distributed in the ICV. The extrusion of sodium in the ECV is then balanced by a passive outflux
of chloride, the main extracellular anion accompanying sodium.

Fluid Balance within ECV Subcompartments
The ECV subcompartments are in close communication with one another. The intravascular
compartment contains 15-20% of the ECV water: intravascular water is tightly regulated as it is
essential for the maintenance of an effective circulation. Intravascular water mainly depends on:
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(a) balance of hydrostatic and osmotic forces between the ECV subcompartments, (b) lymphatic
system, (c) the kidneys in concert with (d) neurohormonal mechanisms. These regulatory systems
closely interact and communicate with one another.

a. Small molecules (e.g. urea, creatinine) and electrolytes (e.g. sodium, potassium and chloride)
diffusive freely and therefore are ineffective osmoles in the ECV subcompartments. Therefore, the
most important effective osmoles are represented by albumin and other plasma proteins. Net
capillary filtration, as the balance of forces regulating water shifts between the intravascular and
interstitial subcompartment, is described by the Starling equation as follows:

Net Capillary Filtration (Jv) = Lp *[(Pc – Pi) – σ (Πc – Πi)]

where Lp stands for hydraulic permeability, Pc and Pi are capillary and interstitial hydrostatic
pressures, Πc and Πi are capillary and interstitial colloid osmotic pressures, and σ represents
Staverman’s reflection coefficient. As a result of the Starling equation, a positive net fluid filtration
into the extravascular subcompartments throughout the whole capillary has been observed
experimentally.2 The result is a continuous net fluid loss from the intravascular subcompartment
to the extravascular subcompartments (Figure 1.2). At steady state, this loss is counterbalanced
by the lymphatic system.
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Figure 1.2: The main forces driving net capillary filtration according to the Starling equation.

Figure generated at BioRender.com

b. The lymphatic system has both an immune and circulatory support function. It is composed of
a specialized vessel network and organs (e.g. lymph nodes), whose main function is to return the
interstitial fluid (lymph) from the tissues back into the circulatory system. About 8 liters/day of
capillary filtrate is transported by the lymphatic vessels back into the intravascular compartment,
with about 4 liters of filtrate transiting through the lymph nodes and the remainder returning into
the circulation through the thoracic duct.
c. The kidneys regulate the intravascular volume mainly by affecting the sodium balance – this
aspect will be covered in detail further below (see paragraph: 1.2 Sodium and the Kidneys).
Intravascular sodium balance regulation, as operated by the kidneys, ultimately affects all ECV
subcompartments.
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d. Neurohormonal regulation of the intravascular volume occurs as the result of an interaction
between input systems (nervous and cardiovascular system) and output systems (the kidneys).
Cardiopulmonary baroceptors, located in the pulmonary artery and cardiac atria sense wall strain
due to filling the pressures and activate compensatory mechanisms to stimulate water and sodium
excretion at the kidney level, by secreting hormones such as the atrial natriuretic peptides.
Renin angiotensin-aldosterone system: a specialized structure located in the kidney tubules (the
macula densa) is able to sense the tubular chloride load and regulate kidney filtration by altering
the vascular tone of the glomerular afferent arteriole via the renin-angiotensin pathway. This way,
the kidney is able to maintain a constant sodium chloride excretion in spite of even large changes
to kidney blood flow, preserving an adequate intravascular volume. Aldosterone acts favoring
distal tubular sodium reabsorption by regulating the expression of sodium transporter proteins,
thus maintaining the intravascular volume. It is partially upregulated by angiotensin II and partially
by other systems. These systems are described more in detail further below (see paragraph: 1.2
Sodium and the Kidneys).

Total Body Sodium and Sodium Distribution within the Body Compartments
As the intravascular compartment is the most easily accessible compartment of the human study,
the first total body ionic (sodium and potassium) balance studies were performed from inferences
based on the ionic content of the intravascular compartment as delineated further below.

In mammals, intracellular tonicity is considered equivalent to the extracellular environment. This
equates to the physiological assumption that intracellular, plasma, interstitial and total body
tonicity are similar. As explained above, sodium and potassium are the two main cations in the
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human body, responsible for ~50% of total body tonicity, the remainder of the total body tonicity
being represented by the associated anions (mainly chloride and bicarbonate, with smaller amounts
represented by inorganic anions such as phosphate, sulphate, etc). Total body sodium and
potassium balance studies by Edelman et al3 have estimated that the ~98% of total body sodium is
contained within the ECV compartment, with the remaining ~2% confined within the intracellular
compartment. This almost mirrors the behavior of potassium, with ~95% located intracellularly
and ~5% extracellularly. Sodium is also the main cation of human plasma, where its physiological
concentrations range ~150 mmol/L, as opposed to potassium at ~4 mmol/L. Early physiology
studies, therefore, posited that tissue sodium and potassium content essentially reflect the balance
between the ECV and the ICV.3

Exchangeable vs Nonexchangeable Sodium
In order to estimate total body sodium, Forbes and other authors devised short-term balance studies
using radioisotope dilution techniques.4,5 The principle behind these methods assumed that a small
amount of radioactive isotope (sodium and potassium), after intravenous injection, would dilute
within all ECV and ICV subcompartments. Measuring residual plasma radioactivity due to these
isotopes, after a relatively short period of time (18-24 hours), would yield an estimate of total body
cations available for exchange between subcompartments. The total body pool of exchangeable
sodium and potassium where thus measured. Total body sodium in humans was estimated by the
radioisotope sodium-24 (t1/2 = 15 hours) dilution techniques. A known amount of radioactive
sodium was allowed to equilibrate within the body for 18-24 hours; at the end of the equilibration
period a plasma sample was taken, while urine was collected continuously during the equilibration
period. Assuming that radioactivity in the plasma, after equilibration, would equate total body
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radioactivity, total body sodium content was calculated as “total exchangeable sodium”, according
to the formula:
Total exchangeable sodium = (24Nainjected – 24Naexcreted)/([24Na]serum/[Na]serum)

then indexed by body weight, returning an estimate of tissue sodium content. The isotopic dilution
method, therefore, measures that portion of the total body sodium which is available for short-term
exchange between body subcompartments. Notably, total exchangeable sodium is opposed to
“non-exchangeable” sodium or “osmotically inactive” sodium, that is the amount of sodium not
available for short-term equilibration: longer-term equilibration studies (up to four weeks, using
sodium-22, with a t1/2 = 2.6 years) coupled with bone biopsies and ashing techniques showed that
a relevant fraction of total body sodium (20-30% of total body sodium) is fixed in crystalized form
within the mineralized skeletal bone matrix.6,7 At the time, however, the metabolic significance of
those sodium deposits in the longer term had not been clearly defined. Normal total body sodium
per kilogram of body weight (including both exchangeable and non-exchangeable sodium) and
exchangeable sodium/kg body weight values were calculated at 54 mEq/kg and 40 mEq/kg,
equating to 0.12% and 0.09% of body weight, respectively.1 Similar techniques were used for total
body potassium using potassium-42, albeit potassium exchange occurred mainly within the ICV
subcompartments.

Osmotically Active and Osmotically Inactive Sodium
Osmotic equilibrium between body compartments is assumed to be mainly determined by the
balance of exchangeable cations (sodium and potassium) and body water, or total body tonicity.
Sodium-24, potassium-42 as well as deuterium water dilution studies in healthy individuals
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allowed the calculation of total body tonicity. The resulting linear equation, initially enunciated by
Edelman et al,3 related the sodium contained in plasma to the amount of exchangeable sodium and
potassium contained in the total body water:

[Na+]P = 1.11 (Nae + Ke)/TBW – 25.6

The advantage of this formula is that it relates a parameter simply measured in clinical practice
(plasma sodium concentration or plasma [Na+]) with three parameters measured as the result of
operationally complex dilution studies. Furthermore, it postulated a predictable quantitative
relationship between sodium balance to potassium and water balance. The slope of the linear
formula predicted a change in a plasma [Na+] of 1.11 mmol/L per unit change in total body tonicity.
The y-intercept (-25.6) in this formula was calculated to be determined by several elements
originally unaccounted for by the original Edelman equation: the presence of comorbid states
(heart, liver, kidney and hormonal disorders), measurement error relative to dilution studies, nonsodium and non-potassium osmotically active solutes such as glucose, serum potassium
concentration and, importantly, sodium and potassium stored in excess of water.8 As a result of
these considerations, this equation has been the subject of a considerable body of subsequent
physiological and mathematical investigations leading to further implementations and
specifications, and its validity is a matter of animated ongoing debate.9,10

Sodium Accumulation in Excess of Water and “Osmotically Inactive” Sodium
In addition to non-exchangeable sodium deposits at the skeletal level, two other organs have been
suggested to accumulate sodium in excess of water – articular cartilage, the skin and the vascular
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endothelium. Whereas the articular cartilage accumulates sodium in an osmotically active, albeit
hypertonic fashion, the skin and the vascular endothelium are thought to be able to store sodium
in a “non-osmotic” or “osmotically inactive” fashion, as they are considered inactive with respect
to plasma [Na+] and total body tonicity, according to the traditional Edelman equation. The
existence of such deposits, especially at the skin level, have been suggested in humans by longterm balance studies, observing that urinary sodium excretion over the long term (days to weeks)
did not match sodium intake, leading to apparent, sizeable sodium accumulation without
commensurate water retention.

Cartilage

The cartilage microenvironment has been long recognized to be hypertonic compared to plasma:
the extremely high intra-articular sodium content (>200 mmol/L) is bound to negatively-charged
glycosaminoglycans (GAG), long linear polysaccharide chains containing sulfate groups
(responsible for the negatively-charged portion). This sodium-GAG complexes are osmotically
active, and osmotic swelling is counteracted by the high hydrostatic pressure generated by a
network of collagen chains.11 These features are responsible for the high degree of cartilage
hydration, its functional and mechanical properties.

Skin

In the second half of 1970, a Russian group of researchers first identified the skin as being another
source of sodium deposition in rats.12 Usual radioisotope dilution studies identified these deposits
as rapidly exchangeable, though outside of the sodium pool contained in the ECV or ICV,
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suggesting the existence of a relevant third compartment able to store exchangeable sodium.13More
than two decades later, subsequent studies led by Titze and colleagues rediscovered that rats fed a
high sodium diet would accumulate sodium in excess of water and potassium at the skin dermis
level, were bound to interstitial glycosaminoglycans, similarly to the cartilage tissue.14–16 In
support of these findings, a high-sodium diet was found to increase the sulfate glycosaminoglycan
content in the skin in several studies, both in rats and humans.17 Skin hypertonicity was speculated
to occur by intradermal kidney-like countercurrent concentrating mechanisms.18,19 Skin sodium
accumulation was found to be immunologically regulated by resident macrophages sensitive to
changes in local changes in interstitial fluid tonicity via a signaling pathway mediated by the
tonicity-enhanced binding protein (TonEBP), which would upregulate glycosaminoglycan
synthesis by interstitial fibroblast as a result of increased interstitial fluid tonicity.17,20,21 This
mechanism also regulates local fluid clearance mechanisms, through the secretion of vascularendothelial growth factor C, which stimulates lymphangiogenesis to increase local lymphatic fluid
clearance.22,23
In humans, the existence of a third compartment for hypertonic sodium accumulation has been
suggested by a spaceflight simulation studies, the Human Behaviour Study (HUBES) and the
Mars500 study, where simulating the conditions of a metabolic ward, participants received food
with a known amount of salt urine was collected daily for the whole duration of the simulation.24–
26

The HUBES study showed the long term behaviour of total body sodium to water intake, after

changing from a low-salt diet to a high-salt diet. Human participants, following an abrupt increase
in dietary sodium intake, underwent an initial increase in body weight for the first 80 days, only to
keep accumulating sodium without changes in body weight, up to 134 days.24 The Mars500 studies
showed that under a constant dietary salt intake, urinary sodium excretion exhibited large
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fluctuations about the mean, following 7-day cycles. Increasing salt intake was immediately
followed by sodium accumulation and an increase in extracellular water, and was eventually
followed by increased salt intake. These large, weekly fluctuations in urinary sodium excretion,
however, were not followed by commensurate extracellular water retention. Altogether, these
studies suggest that sodium can be stored in excess of water and released rhythmically.26
From an evolutionary perspective, these sodium reservoirs act as a buffer system in response to
acute hypotonic and hypertonic loading, preventing acute shifts in plasma osmolarity (harmful to
the central nervous system), or to prevent sudden ECV expansion. Indeed, the skin’s inability to
“sequestrate” sodium via these mechanisms was associated with intravascular volume expansion,
and sodium-sensitive hypertension.27 Recent studies have also shown that hypertonic skin sodium
reservoirs may serve to enhance the antimicrobial barrier provided by the skin.28 Conversely,
excessive skin sodium deposition, as well as defects in lymphatic clearance mechanisms, have
been associated with vascular endothelial nitric-oxide synthase dysregulation and sodiumsensitive hypertension.20

Endothelial Glycocalyx

Recently, an additional sodium-buffering system was also described at the vascular endothelium
level: the endothelial surface layer or “endothelial glycocalyx”.29 This is a layer of proteins
attached to glycosaminoglycan groups (such as heparan sulfate and hyaluronic acid), thought to
have vasoregulatory and immune-regulatory functions.30 More recently, several authors suggested
that the endothelial surface layer may also have intravascular sodium buffering function, nondissimilarly than the skin. 31–33 Studies showed that intravascular sodium loading, occurring either
due to hypertonic saline infusion or due to high dialysate [Na+] during hemodialysis (HD)
14

treatments, resulted in local osmotic stress and glycocalyx “shedding”, i.e. losing molecular
components.31–33 Impaired endothelial surface layer function is associated with increased
microvascular permeability and has been speculated to lead to increased sodium accumulation at
the skin level.30
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1.2 Sodium and the Kidneys
One the main functions of the kidneys is the maintenance of the water and electrolyte balance.
Each of the two kidneys contains ~1,000,000 structural and functional units – the nephrons – in
human adults.34 A nephron is composed of a vascular subunit, the glomerulus, made of a
convoluted tuft of capillaries and connected to a tubular epithelial subunit, the tubule, via
Bowman’s capsule.
Blood enters the glomerulus from the systemic arterial circulation via the afferent artery and exits
the glomerulus via the efferent artery, through the peritubular capillaries, key in the reabsorption
process, and back into the systemic venous circulation. The main function of the glomerulus is the
filtration of blood plasma through a barrier made of three layers: (a) the fenestrated glomerular
endothelium, (b) the glomerular basal membrane and (c) a layer of specialized cells – the
podocytes. These cells have elongated foot processes forming small slits in the filtration barrier
that allow the selective filtration of molecules. This barrier is selectively permeable to small solutes
(such as electrolytes, small molecules such as urea and creatinine), and with limited permeability
to proteins. The fluid resulting from the filtration process – ultrafiltrate – enters the tubule via
Bowman’s capsule.
The tubule is a hollow structure made by specialized epithelial cells with different absorption and
secretive properties, mediated by specialized ionic channels and transport proteins located on the
apical (luminal) and basal side of the cell. According to different epithelial cell populations
accounting for specific solutes and water permeability and reabsorption properties, the tubule can
be divided in several different segments (Figure 1.3):
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Figure 1.3: Schematic representation of the kidney nephron.
In each segment of the kidney tubule, purple arrows represent primary and secondary active transport mechanisms
(absorption and secretion), whereas blue arrows represent passive transport mechanisms.

Figure generated at BioRender.com

● The proximal tubule, responsible for active mass reabsorption of several molecules that
cross the glomerular filtration barrier. This process occurs via active transporters using
energy in the form of adenosine triphosphate and passive transporters, exploiting
transtubular solute concentration gradients. The entirety of aminoacids, glucose and small
17

peptides and proteins is reabsorbed at this level in normal conditions. Large amounts of
sodium (~65%), potassium (~45%), chloride and bicarbonate are also reabsorbed at this
level.
● The loop of Henle, comprising a thick descending limb, a thin descending and ascending
limbs, the thick ascending limb, and the macula densa. This portion of the tubule has
several functions. Firstly, it reabsorbs large amounts of electrolytes (e.g. 25-30% of sodium
is reabsorbed at this level). Secondly, it is responsible for the urine concentration and
dilution processes. Thirdly, it acts as a feedback mechanism in tandem with the glomerulus
to regulate glomerular blood flow: the macula densa is a specialized tubular cell
conglomerate belonging to the juxtaglomerular apparatus. It is responsible for the
regulation of the vascular tone of the afferent arteriole in response to tubular salt delivery:
briefly, increased tubular chloride delivery is sensed by the macula densa, which secretes
vasoactive substances and causing vasoconstriction of the afferent arteriole, thus reducing
glomerular blood flow and the filtered load.35 Viceversa, a reduced tubular chloride
delivery block secretions of these vasoactive molecules and results in vasodilation of the
afferent arteriole, increasing glomerular blood flow and filtered load. This process is
known as tubulo-glomerular feedback.
● The distal tubule, further separated into three segments – the distal convoluted tubule, the
connecting tubule, the collecting tubule. The distal convoluted tubule reabsorbs sodium
chloride through a thiazide diuretic-sensitive cotransporter (~5% of total reabsorbed
sodium). The collecting tubule is responsible for the final portion of sodium reabsorption
(~3%) via the epithelial sodium channel (ENaC), upregulated by cortical adrenal hormones
– mineralocorticoids such as aldosterone, and glucocorticoids such as cortisol. This portion
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of the tubule is also responsible for final urine concentration: the conditional expression of
tubular water channels (aquaporins) in response to posterior pituitary gland release of the
antidiuretic hormone leads to free water reabsorption of urine concentration. The
connecting tubule covers an intermediate function between the two segments.

Glomerular Filtration Rate
One of the main measures of kidney function used in physiology and clinical medicine is
glomerular filtration rate (GFR). This is the volume of plasma filtered by the kidney glomeruli per
unit of time. Normal GFR values stand between 100-120 ml/min, with a physiological decline of
~1 ml/min/year of age. Pathological declines in GFR may be due to either acute or chronic disease
processes of the kidneys. GFR can be measured experimentally by measuring the clearance (i.e.
the volume of blood completely cleared from a substance per unit of time) of some specific
molecules by the kidneys, as long as they are freely filtered into the tubules, and their secretion
and reabsorption is negligible. Examples of such molecules are the exogenous molecules inuline
and iothalamate. In clinical practice, creatinine clearance is more commonly used, as creatinine is
an endogenous molecule resulting from the catabolism of muscle creatine, and whose plasma
levels increase with decreasing GFR. In the last decades, GFR has been clinically estimated
(eGFR) from steady state plasma creatinine levels, using linear regression formulas derived from
population-based studies.36,37

Regulation of Renal Sodium Excretion: Glomerulo-tubular balance.
In relation to the amount of filtered sodium, only less than 1% of filtered sodium is excreted in the
final urine under normal conditions. This balance is maintained even in situations of significantly
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increased filtered sodium loads, meaning that tubules can regulate their reabsorption capacity even
in situations of large increases inGFR. This phenomenon, called glomerulo-tubular balance, can
be enunciated as: “sodium reabsorption in a given nephron segment is proportional to sodium
delivery in that segment”.34
This process occurs in several tubular segments, each with specific mechanisms. At the proximal
tubular level, an increase inGFR results in increased filtration fraction, with increasing oncotic
pressure in the peritubular capillaries, favoring tubular reabsorption and reduced sodium excretion.
The resulting increase in filtered load of glucose and aminoacids is also associated with increased
sodium reabsorption. At the distal tubular level, sodium reabsorption is even more critical
compared with the proximal tubule – although quantitatively less significant, distal sodium
regulation is the final regulatory step before excretion and is therefore the critical step to determine
final urinary sodium excretion.38 This final regulatory step is mainly under the control of
aldosterone and cortisol, with their regulatory function on ENaC expression and sodium
reabsorption.38

Sodium Balance and Kidney Disorders
Chronic kidney disease (CKD) is an umbrella term encompassing all kidney disorders that result
in a sustained reduction in GFR for at least 6 months.39 Numerous different etiologies underlie the
development of CKD and result in widely different glomerular and tubular function derangements.
Nonetheless, the general consensus is that CKD is a condition prone to developing sodium
accumulation, this being reflected both from studies investigating the pathophysiology as well as
the epidemiology of sodium balance in CKD.38,40
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The main mechanisms underlying sodium accumulation in kidney disorders can be divided in (a)
reduced filtered sodium load and (b) increased tubular sodium reabsorption. As for point (a),
significant reductions in the filtered sodium load are typical of advanced CKD stages or severe
acute kidney injury, where severe reductions in GFR ensue. As for point (b), conversely, several
mechanisms concur to determine an increased tubular sodium reabsorption in CKD:38

1. Reductions in kidney mass (observed from experimental forms of surgical CKD with
removal of 5/6th of the total kidney mass), result in an imbalance in sodium reabsorption,
where it decreases in the proximal tubule,41 while it increases by four to five times in the
distal tubule, due to the upregulation of the sodium transport proteins therein located.42
2. CKD is associated with increased circulating aldosterone levels, both due to traditional
(high plasma renin activity and hyperkalemia)43–45 and non-traditional activation
mechanisms (e.g. acidosis, endothelin-1, vasopressin, adrenocorticotropic hormone
secretion).46,47 Aldosterone secretion is then associated with increased distal tubular
sodium reabsorption.
3. Activation of the intrarenal renin-angiotensin system: indeed, proximal tubules have been
shown to be able to synthetize angiotensinogen,48 which can be activated it into angiotensin
II via renal renin and angiotensin-converting enzyme expressed throughout the nephron.49
Tubular angiotensin II can activate ENaC in the distal nephron, promoting distal sodium
reabsorption.50 These mechanisms are overactive in CKD, especially in diabetic kidney
disease.51,52
4. Increased chloride intake has been associated with increased distal sodium reabsorption in
individuals with salt-sensitive hypertension: as the accompanying anion of sodium in salt,
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high chloride intake activates the aldosterone receptors and distal sodium reabsorption in
this subset of individuals.53,54
5. Acid loading, such as the one that normally occurs in protein-rich Western diets, stimulates
several mechanisms of increased kidney proton excretion (including the renin-angiotensin
system, aldosterone and endothelin-1).55 In CKD, however, these mechanisms are
incapable of completely excreting the ingested acid loading due to the reduction in nephron
mass: the resulting metabolic acidosis further stimulates these mechanisms initiating a selfsustained vicious cycle. These mechanisms converge on distal proton secretion, mediated
by H+-ATPases that require the maintenance of electroneutrality to work, thus stimulating
ENaC-mediated distal sodium reabsorption.55
6. This final mechanism is extremely relevant to a subset of kidney disorders characterized
by urinary protein loss (proteinuria) due to selective damage to the glomerular membrane.
One such disorders is diabetic kidney disease, where chronic glucose exposure results in
endothelial protein glycation and kidney glomerular capillary damage, with varying
proteinuria severity. In nephrotic syndrome, congenital or acquired defects in the
glomerular membrane result in massive urinary protein loss, low serum protein levels,
sodium/water retention and edema formation. Proteinuria has been shown to directly
activate the ENaC and subsequent sodium reabsorption: this mechanism is mediated by
plasminogen, a serin-protease excreted in the urine among other proteins: plasminogen is
activated into plasmin inside the tubular lumen and activates the ENaC by cleaving the
ENaC γ-subunit, thus releasing an inhibitory peptide.56 Plasminogen excretion has been
shown to increase proportionally with the severity of proteinuria: therefore, kidney
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disorders with more severe proteinuria have also been associated with more severe sodium
retention.57–59

As CKD is an extremely heterogenous disease, different combinations of the above mechanisms
may be at play to determine increase distal sodium reabsorption – if present.38 Indeed, he
determination of urinary sodium handling in CKD and its causes is an extremely understudied
field, both at the epidemiological and experimental level. This is likely the consequence of the lack
of reliable and validated tests to objectively evaluate urinary sodium excretion in clinical practice,
the variability in daily dietary sodium intake and urinary sodium excretion,25,60 the compliance
challenges associated with long-term, complete urine collections, and the multitude of etiologies
underlying CKD, with a relevant fraction of CKD having no diagnosis due to diagnostic limitations
of modern-day nephrology.61
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1.3 Physiology of renal replacement therapies – HD and PD
Severe impairments in renal function, up to levels of eGFR <15 ml/min/1.73m2, in presence of
either ECV overload, metabolic disorders and/or symptoms of “uremia”, require the initiation
renal replacement therapy in order to support life. Excluding renal transplantation, which is not
going to be treated in this work, two main options of renal replacement therapy exist at present:
HD and PD. The physiology of dialysis is an extremely wide topic, therefore for the purpose of
this work, only the aspects relative to volume and sodium removal are going to be presented.

Maintaining a neutral sodium balance is one of the main goals of renal replacement therapy.
Sodium intake must be equal to urinary sodium excretion (when there is meaningful residual
urinary output) and removal through renal replacement therapy.
Though noting the recently described incongruencies between total body sodium and the ECV due
to osmotically inactive sodium deposits (see paragraph: 1.1 Sodium and Compartment
Physiology), according to traditional physiology, sodium intake is considered a fundamental
determinant of the ECV status, as it determines thirst and subsequent water intake: an increase in
plasma tonicity, primarily (but not only, with hyperglycemia in diabetes being a notable
exception)62 driven by increased plasma [Na+], is detected by the osmoceptors located in the
hypothalamus, driving thirst and vasopressin secretion by the posterior pituitary gland.63,64
Vasopressin secretion acts on the collecting tubules by stimulating the reabsorption of free water.
This is an extremely sensitive mechanism – even a ~2% increase in plasma tonicity is sufficient to
promote fluid intake, regardless of age.65 Humans tend to maintain plasma [Na+] relatively
constant around a fixed value, the plasma “sodium setpoint”, according to the above mechanisms.
This also applies to patients requiring renal replacement therapy even in absence of a meaningful
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residual kidney function – pre-dialysis plasma [Na+] shows little variability in repeated measures
over time in this population, mainly as a function of thirst regulation.66,67
Sodium intake generally encompasses: [a] dietary sodium intake, mainly by ingesting food
containing naturally present or added sodium, [b] sodium contained in commonly prescribed
medications (e.g. sodium bicarbonate, or antibiotics) or [c] via the infusion of intravenous fluids
like saline, for hospital inpatients.
Residual urinary output is of primary relevance in patients on renal replacement therapy, and its
preservation has been associated with better survival:68,69 residual urinary output allows the
maintenance of urinary sodium excretion in-between dialysis sessions, and better control of ECV
balance due to urinary sodium excretion, preventing the hazards of high ultrafiltration rates during
HD.70,71

The Physiology of Sodium Removal in Renal Replacement Therapy
Sodium removal in renal replacement therapy occurs via two different biophysical principles:
convection and diffusion. These principles describe solute movement across a semi-permeable
membrane:
● Convection occurs when a pressure gradient (either hydrostatic or osmotic) is applied
across a semi-permeable membrane: water moves across the membrane and drags sodium
and other molecules along, as a function of water flow. In HD, the pressure gradient is
generated by applying a negative hydrostatic pressure in the dialysate compartment, in
order to remove water and sodium; in PD, the pressure gradient is generated by instilling
high glucose-containing solutions inside the peritoneal cavity.
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● On the other hand, diffusion occurs when sodium moves across the semi-permeable
membrane as a function of the concentration gradient of sodium in the two sides of the
membrane. In both HD and PD, the concentration gradient of sodium is generated by
manipulating [Na+] in the dialysate solution, according to the following formula:
[Na+]gradient = [Na+]dialysate - [Na+]plasma

Where [Na+]plasma, in this setting, is equal to the plasma sodium setpoint. A negative gradient will
determine diffusive loss of sodium to the dialysate, whereas a positive gradient will result in
diffusive sodium gain. In case of a null gradient, no sodium loss or gain will occur.72
Positive sodium gradients also tend to increase the plasma sodium setpoint over time, and are
strongly associated with thirst and increased weight gain in-between dialyses sessions.73,74
Other factors, however, intervene in influencing the diffusion of sodium across the dialysis
membrane. In principle, two main aspects need to be considered: the activity of sodium in the
solution and the dialysis membrane.72
Plasma is a complex solution, containing about 94% water, electrolytes and small molecules, and
6% proteins and lipids. In this setting, not all sodium ions contained in the solution are available
for diffusion, but only the sodium ions that are non-complexed (e.g. to anions such as bicarbonate,
phosphate, or proteins) and electrochemically active.72 In practice, dialysate [Na+] needs to be
calibrated against active plasma sodium, rather than plasma [Na+].
As previously mentioned, diffusive sodium transport is affected by the presence and properties of
the dialysis membrane.75 By interacting with the electrically charged membrane, plasma proteins
coat the dialysis membrane surface and form a gel that generates resistance for sodium ions to
transit across. Furthermore, because of the selective permeability of the dialysis membrane,
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negatively charged plasma proteins like albumin do not cross the barrier; in order to maintain
electroneutrality, these proteins trap cations like sodium, and blunt its activity.72 This phenomenon
is termed the “Gibbs-Donnan effect”. The practical consequence of the Gibbs-Donnan effect is
that, when applying convection alone, the generated ultrafiltrate has a lower [Na+] compared with
the plasma.76,77 To generate ultrafiltrate with the same [Na+] as the plasma (“isonatric”), a negative
diffusive gradient needs to be generated, where the dialysate [Na+] is about 4-7% (5-10 mmol/L)
lower than plasma [Na+].77,78 If dialysate [Na+] is maintained above the “isonatric” threshold,
sodium diffuses from the dialysate compartment to the plasma, and the net result is sodium
accumulation with respect to water. This phenomenon generates an imbalance between sodium
and water removal – when water removal exceeds sodium removal, plasma [Na+] rises, further
stimulating thirst, weight gain and ECV expansion.66 Therefore, diffusion is necessary to maintain
an optimal balance between sodium and water removal.79,80
In HD, most of the sodium removal is usually achieved via convection: in one study, convection
was estimated to account for at about ~80% of interdialytic sodium removal and was closely
related to ultrafiltration volume; diffusion, conversely, as it closely depends on the [Na+]gradient,
was highly variable (also including intradialytic diffusive sodium gain) and accounted for ~20%
of interdialytic sodium removal on average.81
Determining the optimal dialysate [Na+] is a clinical challenge. As the main plasma osmolyte,
sudden reductions in plasma sodium result in reduced plasma osmolality and intravascular
volume.82 Thus, high dialysate [Na+] are necessary to maintain intradialytic hemodynamic stability
and to prevent brain osmotic imbalances (dialysis disequilibrium syndrome): short, highly efficient
HD treatments require high ultrafiltration rates to remove excess volume and cause rapid drops in
plasma osmolarity (due to uremic toxin removal, such as urea).80 Both also result in a rapid
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reduction of the intravascular plasma volume and are associated with significant drops in blood
pressure (BP) and organ (heart, brain, kidney, gut) ischemia during HD.83,84 Using high dialysate
[Na+], however, also has important shortcomings. The effects of high dialysate [Na+] on
exchangeable total body sodium, combined with shorter dialysis treatments have been shown as
far back as 1979 (Figure 1.4), where patients with shortest treatment times (14.8 hours per week)
and highest dialysate [Na+] (136 mmol/L) had a 25% higher mean total body exchangeable sodium
per kg of lean body mass, compared with patients receiving 18-21 hours per week with a dialysate
[Na+] of 130 mmol/L.85
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Figure 1.4: Summary of the 1979 study by Sellars et al, showing incremental exchangeable sodium deposits as dialysate [Na +]
increased and weekly treatment time decreased.85

As a modern comparison, contemporary prescription practices commonly entail 12 hours per week
(or less) and dialysate [Na+] of 140 mmol/L,79,80 and may result in even larger ECV expansion than
evidenced at the time. This hypothesis is supported by the overwhelming rates of hypertension and
cardiovascular disease currently observed in patients treated with standard HD practices.86–88
In spite of suggestive evidence provided by single-center experiences such as Tassin, France, or
Turkey, where optimal ECV and sodium balance is achieved via longer HD treatments with
optimized convective and diffusive sodium removal, leading to better BP control and survival
benefits,89,90 contemporary lifestyle, structural and economic pressures have led to the common
adoption of shorter dialysis sessions and high dialysate [Na+].

Sodium Accumulation: extracellular volume expansion and outcomes
The expansion of the ECV is a common complication encountered in patients undergoing renal
replacement therapy, manifesting itself with peripheral (e.g. ankle, lower limbs) and central (e.g.
pulmonary) edema.91 Expansion of the ECV and its subcompartments is associated with an
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increase in total body sodium, with adverse effects on the cardiovascular system: hypertension,
cardiac hypertrophy, heart failure, acute coronary syndrome and stroke.92,93 This is especially
relevant in patients with CKD and kidney replacement therapy, where cardiovascular disease is
the main cause of death in this population.94

Extracellular volume management with dialysis
One of the main goals of dialysis is maintaining an optimal ECV balance by removal of excess
sodium and water. The optimal ECV corresponds to the patients’ “dry weight”, and is defined as
“the absence of signs and symptoms of volume overload or volume depletion”.79 The dry weight
is estimated clinically by each individual clinician using physical examination (e.g. pitting edema,
jugular vein distention, pulmonary crackles, signs of pleural effusion, ascites), with the aid of
several diagnostic tools, such as chest imaging (x-ray, computed tomography), point-of-care
ultrasound and bioimpedance spectroscopy.
When suspecting ECV expansion, the dry weight is clinically challenged by “probing” it –
attempting to remove extra sodium and water during HD.95 Because of the lack of a standardized
definition of dry weight, with low sensitivity and specificity of the clinical assessment and the
currently available diagnostic tools, estimating the dry weight comes at the tangible risk of both
over and underestimation. An overestimated dry weight is associated with ECV expansion and
adverse outcomes.96 Conversely, underestimating the dry weight is associated with ECV
contraction and clinical complications such as intradialytic hypotension, due to reduced
intravascular volume.97,98
Therefore, the achievement of a “correct” dry weight is challenging. At the same time, intradialytic
volume removal is limited by the amount of volume that can be safely removed during a single
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dialysis session. Indeed, excessive volume removal per unit of time during dialysis is associated
with symptoms of reduced intravascular volume (e.g. hypotension, vascular access thrombosis,
organ ischemia, nausea, vomiting, loss of consciousness, cardiac arrest) and is susceptible to renal
replacement therapy-related factors (e.g. treatment time, modality, temperature, dialysate fluid
content), as well as individual factors based on comorbidities, anthropometry and
demographics.99,100 This is especially true with current HD practices, characterized by relatively
short, intermittent sessions – four-hour, three-time weekly HD, where the treatment time to achieve
the ECV goals is limited.

31

1.4 Introduction to 23Na MRI
Magnetic resonance imaging (MRI) is a medical imaging technique that uses a strong magnetic
field and nonionizing radiofrequency energy to polarize the magnetic spins of susceptible nuclei
in biological tissues. In its most commonly available form, MRI manipulates the spins of protons
(1H) contained in biological tissues to generate medical images. Recent technological
improvements, however, allow other nuclei with spin properties that make them susceptible to
nuclear magnetic resonance to be imaged. Sodium-23 (23Na) is one of such nuclei. The properties
that reduce the MR sensitivity of non-1H nuclei, and therefore make multi-nuclear imaging more
technically challenging, are the following:
[a] a lower gyromagnetic ratio (γ), which translates into a lower to the Larmor frequency,
according to the formula ω0 = γ * B0 , where B0 (“B-nought”) is the static magnetic field of the MR
magnet;
[b] the spin properties of the nucleus of interest, which influence its relaxation properties;
[c] a lower in-vivo abundance of the nucleus of interest.
Sodium-23 (23Na) is by far the most prevalent sodium isotope in nature and biological systems. It
represents the only stable sodium isotope in nature with an almost 100% abundance. Although
twenty other sodium isotopes have been identified in trace quantities, only two have potential
significance in medicine, 22Na and 24Na. They are characterized by radioactive beta decay, with a
half-life of ~2.6 years and ~15 hours, respectively. Their use in medicine is limited to nuclear
medicine for dilution studies to determine total body exchangeable sodium, as detailed previously.
Conversely,

23

Na is the only relevant sodium nucleus for MRI. Its gyromagnetic ratio is 11.26

MHz/T, approximately 26% of 1H (42.58 MHz/T). It has a spin of 3/2 and a quadrupolar moment.
In biological tissues, this results in a relatively short longitudinal (T1) relaxation (ranging 12-55
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msec) and a bi-exponential transverse (T2) decay, with T2short in the order 0.5–5 msec (which
constitutes 60% of the signal) and T2long (which constitutes 40% of the signal) in the order 15–30
msec.101 Its natural abundance in the human body is about ~0.1% of the human body weight.3 All
these factors net to a signal-to-noise ratio (SNR) between 3,000-20,000 times lower compared with
1

H MRI.101,102

Although the first publications in sodium MRI date back to the 1970s,103,104 an increasing interest
in 23Na MRI has sparked starting from the 1990s, with the development of higher field strength
magnets (≥ 3.0 T) that allow a better SNR, which can be traded for an increased spatial resolution
and/or decreased scanning time. With a lower Larmor frequency compared with 1H,

23

Na MRI

requires dedicated custom-made transmit-receive radiofrequency coils. Other technological
improvements entail radiofrequency coils, computational power and pulse sequences with shorter
signal acquisition times.
The development of pulse sequences with ultra-short echo times (UTE) now allows the acquisition
of MR signal from tissues with extremely short T2 due to their properties (e.g. cortical bones or
lungs, with 1H) or nuclei with rapid transverse decay, such as 23Na.
Rudimentary UTE pulse sequences utilized a nonselective hard pulse, with an echo time of 2-4
msec.105 Shorter echo times (< 1 msec) have been later achieved by using non-cartesian pulse
sequences, with radial or spiral signal acquisition, where most of the signal is collected from the
center of k-space, where all radial projections start – this allows enhanced image contrast and
reduced motion artifacts. This comes at the expense of final image resolution and image blurring.
At present, common pulse sequences employed for

23

Na MRI are mainly 3D radial and twisted

projection imaging, both with density adaptation to fill the k-space homogeneously and improve
the point spread function of the signal acquisition methods.106
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By using “long” TR and ultra-short TE, UTE pulse sequences allow the collection of sodium-23
spin density-weighted images. This is the simplest way to quantify tissue [Na+]. Such is also the
pulse sequence employed for this research work.
Echo times (TE) in the order of few milliseconds can be achieved via different approaches. One
such approach is “two-dimensional radial imaging”, where k-space is acquired following radial
projections during the frequency encoding step (Figure 1.5), by manipulating the gradients on the
x and y planes. Such a pulse sequence only uses gradients for slice selection and frequency
encoding – there is no phase encoding step, allowing for very short TE. Total imaging time,
therefore, is the result of this formula (per single slice):
Total imaging time = NSA * TR * NRP
Where: NSA = number of signal averages; TR = repetition time; NRP = number of radial projections.
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Figure 1.5: A representation of k-space as acquired by two-dimensional radial imaging.
k-space is the location in which the MR signal is coded. Each point along the radial trajectories is defined by the spatial
frequencies kx and ky, in terms of inverse distance (1/cm or cycles per cm).

Sodium quantification
To translate the sodium signal in images into [Na+], calibration vials (phantoms) containing known
concentrations of sodium and relaxation times are included within the field-of-view. Solutions
containing NaCl in either liquid or gel form (using agar) are commonly employed, with [Na+]
ranging from 10 mmol/L to 350 mmol/L, depending on the body location of interest. The signal
generated by these phantoms is then calculated selecting a region of interest on the image, and
used to measure tissue [Na+] by linear regression, after correction for relaxation times.
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Mechanisms Underlying Increased Tissue [Na+] and Potential Applications
The interest surrounding

23

Na MRI is the ability to provide a different contrast parameter,

compared with 1H MRI. Indeed, several mechanisms underlie an increase in tissue [Na+]. First, as
sodium is mainly an extracellular cation with an approximate concentration of 150 mmol/L,
increased tissue [Na+] may indicate an increased ECV in the tissue of interest. This is likely the
most significant mechanism of increased tissue [Na+], and this concept is closely connected, in
23

Na MRI, with the problem of “partial volume effect”.107 At 3.0 T field, an approximate resolution

of 3x3x30 mm3 is usually achieved. Within its volume, each voxel includes different tissues in
different proportions, such as fluid (e.g. fibrosis or edema), fat, cellular mass (e.g. muscle tissue):
therefore, the extracellular to intracellular volume ratio within a voxel is a main determinant of
signal intensity, as 23Na signal in the image is an average of all sodium within this volume, with
fat tissue acting as a confounder (acting as ECV but poor in sodium content) (Figure 1.6).
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Figure 1.6: 23Na signal as a function of the extracellular to intracellular volume ratio, due to the partial volume effect. White
circles stand for cell mass within the extracellular space.

Secondly, tissue ischemia may result in dysfunction of the Na+/K+ ATPase, resulting in increased
intracellular [Na+].102 This mechanism is relevant when evaluating image contrast in organs where
ischemic damage is a possibility, such as cardiac tissue after myocardial infarction.108 Other
mechanisms are related to changes in tissue composition as a result of cancer growth (e.g. acidosis
due to dysfunction of the Na+/H+ exchanger, inflammation, fibrosis, neoangiogenesis), or ionic
channel dysfunction, typical of some rare neuromuscular disorders.101,109 Extracellular [Na+] is
also highly regulated at the kidney level, with the concentration gradient between the cortex and
medulla being a promising biomarker of the kidneys’ urine concentration ability.110 The listed
mechanisms of increased tissue [Na+] suggest that 23Na MRI has numerous applications in clinical
practice.
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Leg 23Na MRI
For the purpose of this work, only the application of this 23Na MRI to the tissues of the leg will be
treated, with particular attention to patients with CKD. As a peripheral limb, the human leg is
convenient to image on an MRI scanner, with the several different anatomical structures for study,
depending on the level: the knee cartilage, the tibia and fibula bones, the posterior (triceps surae),
lateral (fibularis longus and brevis) and anterior skeletal muscles (tibialis and extensor digitorum
muscles), fat and skin tissue (Figure 1.7).

Figure 1.7: Summary of the leg cross-section with 23Na MRI.
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The triceps surae muscle and the skin are going to be the main object of interest in the studies
mentioned below.
23

Na MRI using a 3.0 T scanner to study the soft tissues of the leg in humans (skin, muscles) with

hypertension was first applied by a German group, while studying the association between primary
and secondary forms of hypertension with tissue sodium deposits.111,112 The authors found older
age and male sex, as well as a particular form of secondary hypertension (primary
hyperaldosteronism, or Conn’s disease) to be positively associated with skin and muscle [Na+]. In
light of the previous physiological studies by the same group,14,113 the authors speculated whether
the increased tissue [Na+] would be due to osmotically inactive sodium accumulation. In addition,
serum Vascular Endothelial Growth-Factor C (VEGF-C), a molecular mediator associated with
interstitial lymphangiogenesis, was associated with increased tissue [Na+], suggesting that
dysfunctional lymphatic drainage of the interstitium would lead to increased tissue sodium, likely
due to local ECV expansion.
These findings where further confirmed in patients affected by CKD receiving dialysis, compared
with healthy volunteers.114,115 In the study published by Dahlmann et al,114 age > 65 years was
associated with greater tissue [Na+]. In this study, 23Na MRI was performed immediately before
and after a single HD session, showing a reduction in tissue [Na+] after the procedure. Sodium
removal by ultrafiltration, as well the dialysate-to-plasma sodium gradient, were calculated for
each HD session, but did not correlate with observed tissue sodium reduction, suggesting that
tissue sodium clearance was not predictable given these variables alone. However, tissue sodium
reduction after HD was greater in patients with higher serum VEGF-C level, suggesting improved
lymphatic clearance during HD: it is therefore likely that interstitial lymphangiogenesis is an
important determinant of sodium and water removal from peripheral tissues.
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In addition, Schneider et al showed that skin [Na+] was associated with hypertrophy of the heart,
an important known predictor of hard clinical outcomes, in patients with CKD.116 The authors
went on to demonstrate that this relationship was independent of ECV status using bioimpedance
spectroscopy, suggesting that osmotically inactive sodium might have been partially responsible
of cardiac hypertrophy.
A later study in human healthy volunteers using

23

Na MRI on a 7.0 T scanner showed sodium

accumulation to occur specifically at the dermal layer of the skin,117 which has been shown to
contain large amounts of proteins containing negatively-charged sulfated carbohydrate chains
(glycosaminoglycans), or proteoglycans, with the ability to bind and “store” sodium by osmotic
inactivation, i.e. accumulation without water.15,17,118,119 A recent study using 23Na MRI with triple
quantum filtering in ex-vivo human skin samples later showed that large amounts of skin sodium
to be bound to these proteins and likely undetectable by

23

sequences, due to its extremely rapid T2 decay properties.120
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Na MRI using standard UTE pulse

1.5 Overarching Hypothesis and Rationale
In the material presented so far, we have summarized the available evidence supporting the
potential clinical relevance of tissue [Na+], as well as the requirements and pitfalls for its
quantification by 23Na MRI. At the time of this work’s inception (2018), several knowledge gaps
concerning tissue [Na+] existed in the literature, despite sodium being recognized as a fundamental
mediator of cardiovascular disease in the CKD and dialysis population. In particular:
● No formal comparison of tissue [Na+] among healthy individuals, CKD patients and
dialysis patients had been made.
● Similarly, no investigations were made in the pediatric CKD population, in spite of these
patients generally having a smaller comorbidity burden (e.g. overt atherosclerosis and
cardiovascular disease, complicated diabetes mellitus, hypertension) that may act as a
confounder to tissue [Na+].
● Tissue [Na+] had been shown to be positively associated with age and serum VEGF-C in
patients receiving HD,114 although no other clinical predictors, such as HD prescription or
biochemical parameters, were investigated.
● Skin [Na+] had been shown to be positively associated with cardiac mass in patients with
CKD, but no data existed on HD patients. 116
● No data concerning clinical outcomes, such as major cardiovascular adverse events (a
composite outcome including several acute diseases such as myocardial infarction, stroke,
pulmonary embolism and death resulting from these causes) or general mortality, had been
published.
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Therefore, as a premise to this work, we hypothesized that tissue [Na+] is a relevant quantitative
imaging biomarker in the CKD, HD and PD population, with significant consequences on the
cardiovascular system and clinical outcomes.
Four projects have been included in this work to verify this hypothesis, and the research aims for
each individual project are summarized below:
Chapter 2. The aims of this project were to (1) explore the differences in tissue [Na+] between
healthy controls, CKD, HD and PD patients, (2) explore the associations of tissue sodium with
standard blood-based biomarkers and (3) assess the reproducibility of tissue [Na+] measurements
by 23Na MRI.
Chapter 3. This project aimed to compare (1) tissue [Na+] in children and adolescents with CKD
against healthy controls and (2) investigate the associations of tissue [Na+] with clinical biomarkers
of kidney function.
Chapter 4. In this project the aims were to investigate the associations of tissue [Na+] with left
ventricular hypertrophy and other markers of left ventricular structure, such as end-diastolic
volume and geometry.
Chapter 5. In this final project, the aims were to (1) investigate the association between skin [Na+]
with mortality and MACE in a cohort of HD and PD patients, and (2) define the clinical predictors
of skin [Na+].
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Chapter 2
Leg Tissue Sodium Concentration in Chronic Kidney Disease and Dialysis Patients by
Sodium-23 Magnetic Resonance Imaging
In this study, we compared [Na+] of the leg tissues with 23Na MRI, in order to understand whether
CKD, HD and PD were associated with tissue sodium accumulation compared with healthy
controls. Furthermore, we explored the predictors of tissue [Na+].

A version of this chapter has been published in the journal “Nephrology, Dialysis,
Transplantation” Qirjazi E, Salerno FR, Akbari A, Hur L, Penny J, Scholl T, McIntyre CW. Tissue
sodium concentrations in chronic kidney disease and dialysis patients by lower leg sodium-23
magnetic resonance imaging. Nephrol Dial Transplant. 2020 Apr 6:gfaa036. doi:
10.1093/ndt/gfaa036. Epub ahead of print. PMID: 32252091. This article is available under the
terms of the Creative Commons Attribution License.

2.1 Introduction
The toxic effects of sodium in CKD patients have been recognized since the 1940s, when Walter
Kempner proposed the “Rice Diet” to manage hypertension by minimizing dietary sodium intake
to 150 mg per day.1 In the first clinical experiences with chronic HD, dietary sodium restriction
and ultrafiltration were the mainstay of treatment, to manage BP and ECV overload.2 Single center
studies conducted in Tassin, France, demonstrated optimal BP control by a strict dietary sodium
restriction regimen and an extended HD treatment duration.3 Furthermore, high dietary sodium
intake has been associated with greater mortality in prevalent HD patients.4
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Our understanding of sodium metabolism has changed significantly over the past twenty years.
Excess body sodium is stored in an osmotically inactive form in the skeleton and soft tissues.5 The
skin acts as a major extracellular sodium reservoir: sodium is bound to negatively-charged
proteoglycans, inactivating the osmotic effects of excess sodium and preventing ECV expansion.6
Local macrophages regulate skin sodium clearance by VEGF-C-mediated lymphangiogenesis, a
significant extrarenal mechanism for the regulation of BP and ECV.7
Estimating dietary sodium intake remains a major challenge in clinical practice due to the
limitations associated with a urinary sodium excretion-based approach.8 In addition, quantification
of sodium deposition within the body has not been possible with clinically available imaging
techniques until recently.
Sodium-23 Magnetic Resonance Imaging (23Na MRI) allows direct visualization of sodium signal
at the tissue level. Kopp and colleagues validated this technique and have shown its feasibility in
humans by acquiring images of the lower leg by measuring directly tissue [Na+] in the skin and
the muscles.9
At present, several basic clinical questions still remain unanswered. Firstly, tissue [Na+] across the
CKD spectrum have never been systematically explored. Secondly, the skeleton has been
identified as a significant sodium reservoir,10 but this compartment has never been investigated
with

23

Na MRI in CKD or dialysis patients- potentially particularly important given the well-

recognized association between disturbances of skeletal metabolism and cardiovascular outcomes
in CKD . Finally, no study has investigated the correlations between tissue [Na+] and standard
clinical biomarkers in CKD patients.
The aims of this study were to explore the differences in tissue [Na+] between healthy controls,
CKD stage 3-5, HD and PD patients, to explore the associations of tissue sodium with standard
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blood-based biomarkers and to assess the reproducibility of tissue [Na+] measurements by
MRI.
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23

Na

2.2 Materials and Methods
Study Design
This was a pilot cross-sectional cohort study. Study participants belonged to four different cohorts:
healthy controls, CKD stage 3 to 5 not on dialysis, chronic thrice-weekly HD, and PD. Each study
participant underwent a study visit during which baseline clinical and demographic information,
blood tests, and proton and 23Na MRI scan of the right or left lower leg were acquired. HD patients
were scanned on a non-dialysis day, during either the long or short interdialytic interval.
This study was approved by the University of Western Ontario Health Sciences Research Ethics
Board and was conducted in compliance with the approved protocol, Good Clinical Practice
Guidelines and all applicable regulatory requirements.

Subjects
Healthy subjects were recruited from London, Canada; study patients were recruited from the
London Health Sciences Centre Regional Renal Program. All participants were 18 years or older
and provided written informed consent. Healthy controls lacked any history of kidney disease,
heart failure, liver cirrhosis or peripheral edema. CKD patients were stage 3-5 according to KDIGO
guidelines,11 and had no indications to start dialysis. Both HD and PD had been established on
their respective dialysis modality for at least 3 months. Subjects were excluded if they were
pregnant, breast-feeding, intending pregnancy, unable to provide consent, or if they had any
contraindication to MRI studies.

Biochemical Measurements
Plasma, serum and blood specimens from each subject were collected, processed and analyzed in
a central laboratory (London Health Sciences Centre, London, Canada) for routine clinical
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biochemistry. eGFR was estimated using the Chronic Kidney Disease Epidemiology Collaboration
formula.12
23

Na MRI Acquisition and Quantification of Tissue [Na+]

To measure tissue [Na+] in the lower leg tissues non-invasively, a multinuclear-capable 3.0-T MRI
(Discovery MR750, General Electric Healthcare, Milwaukee WI) was used to acquire proton and
sodium images. Subjects were positioned supine in the magnet bore with the thickest part of their
right, otherwise left, calf muscle at the center of a custom-made 23Na birdcage radiofrequency (RF)
coil. Calibration vials with 10, 20 and 40 mmol/L of saline were placed in the RF coil, over the
subjects’ shins. Axial proton T1-weighted Spoiled Gradient Recalled Echo (SPGR) sequences
were acquired to delineate the anatomy of the lower leg. A single-slice

23

Na MR image was

obtained with 23Na-optimized pulse sequence, with the following parameters: slice-selective RF
pulse with a 90° flip angle, TR/TE: 100/1.2ms, total acquisition time: 30min, number of signal
averaging: 100, slice-thickness: 30mm, and isotropic field of view/resolution: 18/0.3cm2.
Maps of tissue [Na+] were generated using an in-house software developed within Matlab
(Mathworks, Natick, USA, R2018a). [Na+] maps were superimposed with the proton-anatomy
images to delineate the regions of interest (Figure 2.1).
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Figure 2.1: Schematic summary of proton (Panel A) and 23Na MRI (Panel B) acquisition. Proton and 23Na images are acquired
separately and superimposed (Panel C) after acquisition for software analysis.

Three regions of interest (ROIs) were drawn, using OsiriX Lite (Version 10.0.5) software,
highlighting different tissues: 1) skin, 2) soleus muscle, and 3) tibial bone (Figure 2.2). Skin,
soleus, and tibial [Na+] in the ROIs were recorded for analysis.
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Figure 2.2: Superimposed Proton and 23Na MRI of the leg for the anatomical selection of Regions of Interest (Tibia, Soleus
Muscle, Skin). The different Regions of Interest are represented by different colored sections.

Data Analysis
Statistical analysis was performed using GraphPad Prism version 8.0.0 for Windows/Mac OS X
(GraphPad Software, San Diego, California USA, www.graphpad.com) and SPSS version 23.0
(IBM Corp. Released 2015. IBM SPSS Statistics for Windows. Armonk, NY: IBM Corp). Normal
distribution was assessed using the Shapiro-Wilk test. Continuous variables were presented as
mean (standard deviation or range) if normally distributed and median (interquartile range) if nonnormally distributed. Categorical variables were expressed as percentages. Comparisons between
continuous variables were assessed with the appropriate parametric and nonparametric tests.
Fisher’s exact tests was used to compare categorical variables. Correlations were assessed by
calculating Pearson correlation coefficient (r) for normally distributed variables and Spearman
correlation coefficient () for non-normally distributed variables; 95% confidence intervals were
computed and a p-value of <0.05 was considered statistically significant. The Bonferroni
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correction was performed to control for type 1 errors when performing repeated correlations for
each given dependent variable.
Measures of effect size were also calculated. Cohen’s d was calculated for power size calculation
for all tissue [Na+]; Cliff’s delta was calculated as a non-parametric effect size measure for skin
[Na+]. We performed sample size calculation for future studies; a power of 80%, with a two-sided
level of significance equal to 0.05 was selected.

Interobserver variability was calculated between three independent raters (FRS, LH, JP). The
intraclass correlation coefficient was computed for each region of interest (skin, soleus, and tibia)
by using the two-way mixed model for single measures and absolute agreement.
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2.3 Results
Baseline Characteristics and Medications
The CKD group consisted of stage 3a (n=1), stage 3b (n=2), CKD stage 4 (n=5), CKD stage 5
(n=4). The HD group included n=13 subjects, with mean HD length 3.8 hours (range 3-4.5 hours)
per session, mean dialysate sodium 139.5 mmol/L (range 136-145 mmol/L), mean dialysate
potassium 2.1 mmol/L (range 1.5-3.0 mmol/L) and a dialysate calcium of 1.25 mmol/L. The PD
group included n=10 subjects on: continuous ambulatory PD (n=2), automated PD (n=5), nocturnal
intermittent PD (n=3), with mean total fluid dwell 9,475 ml/day (range 6,000-11,500 ml/day).
Glucose-based solutions contained a [Na+] of 132 mmol/L, while icodextrin-based solutions
contained 133 mmol/L.
Table 2.1 shows baseline demographics, comorbidities, etiology of kidney disease, and
medications in the four groups. Mean age and sex distribution were comparable across all groups.
Body weight (p=0.02) and BMI (p=0.05) were significantly different. Mean dialysis vintage did
not differ significantly between HD and PD (p=0.24). eGFR was significantly lower in CKD
patients vs controls (CKD: 23.1±11.8 ml/min/1.73m2; Controls: 88.1±16.1 ml/min/1.73m2,
p<0.0001) and PD patients had significantly higher residual urinary volume vs HD (HD: 100
ml/24h, IQR 0-285 ml24h; PD: 1125 ml/24h, IQR 450-1,700 ml/24h, p=0.0002). The prevalence
of hypertension was significantly different between groups (p<0.0001); no significant differences
were observed in the prevalence of other reported comorbidities.
A significant difference in prescribed medications was observed between groups: β-blocker,
calcium channel blocker and diuretics (p-values: 0.002, 0.03, and <0.0001, respectively). Of note,
all PD patients were on loop diuretic therapy.
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Table 2.1: Baseline characteristics in the four groups (Controls, CKD, HD, PD).

Characteristics
Demographics
&
Anthropometrics
Age, years, mean (SD)
Sex (Male/Female)
Weight, kg, mean (SD)
Height, cm, mean (SD)
BMI, kg/m2, mean
(SD)
eGFR, ml/min/1.73m2,
mean (SD)
Residual
Urinary
Volume
ml/24h,
median (IQR)
Dialysis
Vintage,
months, median (IQR)
spKt/V, median (IQR)
Weekly Kt/V, median
(IQR)
Comorbidities
Hypertension, %
Coronary
Artery
Disease, %
Cerebrovascular
Disease, %
Peripheral
Vascular
Disease, %
Congestive
Heart
Failure, %
Diabetes Mellitus, %
COPD, %
Etiology of Kidney
Disease
Vascular Nephropathy,
%
Diabetic Nephropathy,
%
Glomerulonephritis, %
Other, %
Medications
ACE-Inhibitor/ARB,
%
α-blocker, %
β-blocker, %
Calcium
Channel
Blocker, %

Control
(n=10)

CKD (n=12)

HD (n=13)

PD (n=10)

p-value

53.3 (19.5)
4/6
70.5 (8.2)
167.3 (7.0)
25.2 (2.7)

66.3 (6.7)
8/4
88.5 (18.6)
166.4 (8.9)
31.7 (4.5)

62.5 (9.1)
9/4
83.9 (22.6)
171.2 (7.5)
28.4 (7.0)

60.3 (10.2)
5/5
83.1 (13.0)
170.3 (8.4)
28.8 (5.0)

0.17
0.45
0.02
0.40
0.05

88.1 (16.1)

23.1 (11.8)

-

-

<0.0001

-

-

100 (0, 285)

1125 (450,
1700)

0.0002

-

-

22.5 (15.6,
61.0)

0.24

-

-

37.0 (13.0,
63.0)
1.48 (1.45,
1.89)

-

-

10.0
0

-

-

-

1.99 (1.60,
2.79)

-

91.7
16.7

100.0
30.8

70.0
10.0

<0.0001
0.22

0

16.7

15.4

10.0

0.60

0

8.3

15.4

10.0

0.64

0

0

30.8

20.0

0.07

10.0
0

58.3
0

46.2
23.1

40.0
10.0

0.13
0.17

-

41.7

38.5

50.0

0.85

-

33.3

38.5

40.0

0.94

-

16.7
41.7

15.4
30.8

0
30.0

0.40
0.80

10.0

58.3

30.8

30.0

0.12

0
0
0

16.7
66.7
41.7

23.1
76.9
46.2

20.0
50.0
60.0

0.46
0.002
0.03
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Diuretic, %
ESA, %

10.0
-

66.7
25.0

23.1
69.2

100.0
50.0

<0.0001
0.17

ACE: angiotensin-converting enzyme; ARB: angiotensin-receptor blocker; CKD: chronic kidney
disease; COPD: chronic obstructive pulmonary disease; eGFR: estimated glomerular filtration
rate; ESA: erythropoiesis-stimulating agent; HD: hemodialysis; spKt/V: single pool Kt/V; IQR:
interquartile range; PD: peritoneal dialysis; SD: standard deviation.

Table 2.2 shows biomarker levels in the different groups. 1,25-OH Vitamin D, Albumin and
Hemoglobin levels were significantly lower in HD and PD patients relative to Controls (p<0.0001).
Conversely, no significant difference was observed in 25-OH Vitamin D. A statistically significant
increase in c-reactive protein and PTH was observed both in HD and PD groups relative to
Controls.

Table 2.2: Biomarker levels in the four groups (Controls, CKD, HD, PD).

Biomarkers
1,25 Vitamin D,
pmol/L,
mean
(SD)
25 Vitamin D,
nmol/L,
mean
(SD)
Albumin,
g/L,
mean (SD)
C-Reactive
Protein
mg/L,
median (IQR)
Hemoglobin, g/L,
mean (SD)
PTH,
pmol/L,
mean (SD)

Control (n=10)

CKD (n=12)

HD (n=13)

PD (n=10)

p-value

98.6 (28.4)

77.0 (32.5)

23.0 (9.8)

23.9 (14.3)

<0.0001

55.6 (36.3)

67.3 (27.5)

61.2 (34.4)

40.9 (28.7)

0.10

43.7 (2.5)

43.3 (2.4)

41.2 (3.6)

36.7 (4.0)

0.0008

0.7 (0.6, 4.9)

2.1 (0.6, 5.2)

8.0 (2.4, 17.6)

8.7 (5.3, 12.9)

0.0007

142.9 (12.8)

117.3 (22.7)

120.3 (15.2)

104.0 (12.6)

<0.0001

4.5 (1.2)

18.8 (16.9)

44.8 (42.9)

35.9 (38.7)

0.001

CKD: chronic kidney disease; HD: hemodialysis; IQR: interquartile range; PD: peritoneal
dialysis; SD: standard deviation.
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23

Na MRI Analysis

Figure 2.3 shows sample

23

Na MR images of the leg from the four patient groups: a qualitative

difference in sodium signal can be observed mainly in the skin and muscles, with HD and PD
showing the most evident differences.

Figure 2.3: Sample 23Na MR images of the leg in 4 sample subjects from each group. The color bar on the right represents
[Na+]in mmol/L. Panel A: Healthy control. Panel B: CKD patient. Panel C: HD patient. Panel D: PD patient. The images show
a progressive increase in the sodium signal eminently in the skin and in the muscle, especially evident in Panels C and D. A
notable increase in tibial sodium can be observed in Panel D.

Tissue [Na+] in the four groups are listed in Table 2.3.

Table 2.3: Tissue [Na+] in the four groups (Controls, CKD, HD, PD). Data presented as mean (SD)

Control (n=10)

CKD (n=12)

HD (n=13)

PD (n=10)

Skin [Na+] (mmol/L)

19.1 (5.5)

28.7 (12.7)

32.8 (14.2)

35.8 (9.3)

Soleus [Na+] (mmol/L)

22.0 (3.5)

27.0 (5.6)

28.1 (6.0)

30.2 (6.1)
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Tibial [Na+] (mmol/L)

10.5 (1.5)

12.9 (3.2)

14.7 (5.1)

15.5 (2.7)

Figure 2.4 shows a statistically significant increase in skin, soleus and tibial [Na+] (Panel A, B, C
respectively) in HD and PD vs controls. Multiple comparisons did not demonstrate statistically
significant differences in the CKD vs other groups, nor in HD vs PD. However, a trend towards a
progressive increase in [Na+] is evident in all compartments, with PD showing the highest [Na+].

Figure 2.4: Between group comparison in mean Tissue [Na+] (Skin, panel A; Soleus, panel B; Tibia, panel C).

*p<0.01 **p<0.001 ***p<0.0001
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Correlation Analysis
Tables 2.4 to 2.7 show the correlations between tissue [Na+] with biomarker levels, demographics
and anthropometrics in controls, CKD, HD and PD, respectively.
In healthy controls (Table 2.4), skin [Na+] was positively associated with age (r=0.67, p=0.03),
BMI (r=0.83, p<0.01) and weight (r=0.69, p=0.03). Soleus [Na+] was also positively associated
with age (r=0.84, p<0.01). Among the biomarkers, only a statistically significant negative
association was observed between serum albumin and tibial [Na+] (r=-0.66, p=0.04).
Table 2.4: Correlation analysis between skin, soleus and tibial [Na+] with demographics, anthropometrics and biomarkers in the
control group.

Demographics &
Anthropometrics
Age (years)
BMI (kg/m2)
Height (cm)
Weight (kg)
Biomarkers
1,25 Vitamin
(pmol/L)
25
Vitamin
(nmol/L)
Albumin (g/L)

D
D

C-Reactive Protein
(mg/L)
eGFR
(ml/min/1.73m2)
Hemoglobin (g/L)
PTH (pmol/L)
‡

Skin [Na+]
(mmol/L)
r (95% CI)

p-value

Soleus [Na+]
(mmol/L)
r (95% CI)

pvalue

Tibial [Na+]
(mmol/L)
r (95% CI)

pvalue

0.67 (0.07 to
0.91)
0.83 (0.43 to
0.96)
-0.08 (-0.68 to
0.58)
0.69 (0.10 to
0.92)

0.03

0.84 (0.43 to 0.96)

<0.01

0.56 (-0.11 to 0.88)

0.09

<0.01

0.38 (-0.32 to 0.82)

0.27

0.34 (-0.37 to 0.80)

0.34

0.82

-0.20 (-0.73 to 0.50)

0.59

0.72

0.03

0.20 (-0.49 to 0.74)

0.57

-0.13 (-0.70 to
0.54)
0.20 (-0.49 to 0.74)

-0.01 (-0.63 to
0.63)
-0.02 (-0.64 to
0.62)
-0.28 (-0.77 to
0.42)
0.67 (N/A) ‡

0.98

-0.44 (-0.84 to 0.26)

0.20

0.21

0.96

0.14 (-0.53 to 0.71)

0.71

-0.43 (-0.83 to
0.27)
0.02 (-0.62 to 0.64)

0.43

-0.50 (-0.86 to 0.18)

0.14

0.04

0.08

0.70 (N/A) ‡

0.07

-0.66 (-0.91 to 0.06)
0.13 (N/A) ‡

0.33 (-0.38 to
0.79)
0.40 (-0.31 to
0.82)
0.37 (-0.39 to
0.83)

0.36

-0.32 (-0.79 to 0.38)

0.36

0.89

0.26

-0.04 (-0.65 to 0.60)

0.90

0.33

0.01 (-0.66 to 0.67)

0.99

-0.05 (-0.66 to
0.60)
-0.18 (-0.73 to
0.51)
-0.21 (-0.77 to
0.53)

Spearman’s correlation coefficient
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0.58

0.96

0.76

0.63
0.58

In CKD patients (Table 2.5), height was negatively associated with soleus and tibial sodium
concentration (r=-0.69, p=0.01 and r=-0.60, p=0.04, respectively), whereas weight was negatively
associated with soleus sodium concentration alone (r=-0.59, p=0.04). Among the biomarkers,
serum albumin was negatively associated with skin sodium concentration (r=-0.60, p=0.04);
hemoglobin was negatively associated with both soleus and tibial sodium concentration (r=-0.65,
p=0.02 and r=-0.73, p<0.01, respectively). In addition, a non-statistically significant negative
correlation between eGFR with soleus and tibial sodium concentration was observed (Soleus: r=0.45, p=0.14; tibia: r=-0.44, p=0.15).
Table 2.5: Correlation analysis between skin, soleus and tibial sodium concentration with demographics, anthropometrics and
biomarkers in the CKD group.

Skin [Na+]
(mmol/L)

pvalue

r (95% CI)
Demographics &
Anthropometrics
Age (years)
BMI (kg/m2)
Height (cm)
Weight (kg)
Biomarkers
1,25 Vitamin D
(pmol/L)
25 Vitamin D
(nmol/L)
Albumin (g/L)
C-Reactive
Protein (mg/L)
eGFR
(ml/min/1.73m2)
Hemoglobin
(g/L)
PTH (pmol/L)
‡

Soleus [Na+]
(mmol/L)

pvalue

r (95% CI)

0.16 (-0.47 to
0.68)‡
0.20 (-0.44 to
0.71)‡
-0.31 (-0.76 to
0.34)‡
0.00 (-0.59 to
0.59)‡

0.62

0.41 (-0.28 to
0.82)‡
0.01 (-0.58 to
0.60)‡
-0.60 (-0.88 to
0.02)‡
0.28 (-0.37 to
0.75)‡
-0.06 (-0.62 to
0.55)‡
-0.12 (-0.66 to
0.50)‡
-0.34 (-0.77 to
0.31)‡

0.22

0.53
0.32
1.00

0.97
0.04
0.37
0.87
0.48
0.29

0.95

-0.09 (-0.66 to
0.56)‡
0.35 (-0.28 to
0.77)
-0.47 (-0.83 to
0.16)‡
-0.04 (-0.61 to
0.56)‡
-0.45 (-0.81 to
0.17)
-0.65 (-0.89 to 0.13)
0.29 (-0.36 to
0.74)‡

0.80
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p-value

r (95% CI)

-0.02 (-0.59 to
0.56)
-0.39 (-0.79 to
0.24)
-0.69 (-0.91 to 0.19)
-0.59 (-0.87 to 0.03)

Spearman’s correlation coefficient

Tibial [Na+]
(mmol/L)

0.21
0.01
0.04

0.26
0.13
0.90
0.14
0.02
0.37

-0.42 (-0.80 to
0.20)
-0.28 (-0.74 to
0.35)
-0.60 (-0.87 to 0.04)
-0.48 (-0.82 to
0.13)

0.17

-0.42 (-0.82 to
0.26)‡
0.19 (-0.43 to
0.69)
0.00 (-0.59 to
0.59)‡
0.05 (-0.55 to
0.62)‡
-0.44 (-0.81 to
0.18)
-0.73 (-0.91 to 0.26)
0.53 (-0.08 to
0.85)‡

0.19

0.38
0.04
0.12

0.17
1.00
0.89
0.15
<0.01
0.08

In HD patients (Table 2.6), age was positively correlated with skin [Na+], although the association
did not quite reach statistical significance (r=0.53, p=0.06). Among the biomarkers, serum albumin
was negatively associated with both soleus and tibial [Na+] (r=-0.81, p<0.01 and r=-0.78, p<0.01,
respectively); hemoglobin was negatively associated with [Na+] in all tissues, although it did not
reach statistical significance in the soleus (skin r=-0.60, p=0.04, soleus r=-0.55, p=0.06, tibia r=0.76, p<0.01).
Table 2.6: Correlation analysis between skin, soleus and tibial [Na+] with demographics, anthropometrics and biomarkers in the
HD group.

Skin [Na+]
(mmol/L)

Soleus [Na+]
(mmol/L)

pvalue

r (95% CI)
Demographics &
Anthropometrics
Age (years)
BMI (kg/m2)
Dialysis
Vintage
(months)
Height (cm)
Residual Urinary
Volume (ml/24h)
spKt/V
Weight (kg)
Biomarkers
1,25 Vitamin
(pmol/L)
25
Vitamin
(nmol/L)
Albumin (g/L)

D
D

C-Reactive Protein
(mg/L)
Hemoglobin (g/L)
PTH (pmol/L)

pvalue

r (95% CI)

0.53 (-0.02 to
0.84)
0.23 (-0.36 to
0.70)
-0.09 (-0.61 to
0.48)
-0.14 (-0.64 to
0.44)
0.01 (-0.56 to
0.57)‡
0.29 (-0.33 to
0.73)‡
0.13 (-0.46 to
0.63)

0.06

-0.24 (-0.78 to
0.50)
-0.40 (-0.79 to
0.22)
-0.07 (-0.64 to
0.55)
0.18 (-0.45 to
0.69) ‡
-0.60 (-0.87 to 0.04)
0.27 (-0.37 to
0.74)‡

0.53

0.27

0.24 (-0.50 to
0.78)
0.02 (-0.56 to
0.59)
-0.81 (-0.95 to 0.40)
-0.27 (-0.74 to
0.37)‡
-0.55 (-0.86 to
0.03)
-0.49 (-0.14 to
0.84)‡

0.77
0.64
0.97
0.33
0.68

0.19
0.83
0.57
0.04
0.39
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pvalue

r (95% CI)

0.33 (-0.27 to
0.74)
-0.01 (-0.56 to
0.54)
0.23 (-0.37 to
0.69)
-0.48 (-0.82 to
0.09)
0.07 (-0.51 to
0.61)‡
0.00 (-0.56 to
0.57)‡
-0.19 (-0.67 to
0.41)

0.44

Tibial [Na+]
(mmol/L)

0.24 (-0.37 to
0.71)‡
0.14 (-0.46 to
0.65)‡
0.17 (-0.43 to
0.67)‡
-0.38 (-0.77 to
0.22)‡
0.52 (-0.06 to
0.84)‡
0.03 (-0.54 to
0.58)‡
0.03 (-0.54 to
0.59)‡

0.43

0.52

-0.25 (N/A) ‡

0.51

0.94

-0.02 (-0.60 to
0.57)‡
-0.78 (-0.94 to 0.32) ‡
0.28 (-0.37 to
0.74)‡
-0.76 (-0.93 to 0.32)‡
0.57 (-0.03 to
0.87)‡

0.95

0.96
0.46
0.09
0.82
1.00
0.54

<0.01
0.39
0.06
0.11

0.66
0.58
0.20
0.07
0.92
0.92

<0.01
0.38
<0.01
0.06

‡

Spearman’s correlation coefficient

In PD patients (Table 2.7), age was positively correlated with soleus [Na+] (r=0.66, p=0.05).
Among the biomarkers, albumin showed a negative correlation with soleus [Na+] (r=-0.65,
p=0.04); PTH showed a positive correlation with tibial [Na+] (r=0.68, p=0.04).
Table 2.7: Correlation analysis between skin, soleus and tibial [Na+] with biomarkers and demographics in the PD group.

Skin [Na+]
(mmol/L)

Soleus [Na+]
(mmol/L)

pvalue

r (95% CI)
Demographics &
Anthropometrics
Age (years)
BMI (kg/m2)
Dialysis Vintage
(months)
Height (cm)
Residual Urinary
Volume (ml/24h)
Weekly Kt/V
Weight (kg)
Biomarkers
1,25 Vitamin D
(pmol/L)
25 Vitamin D
(nmol/L)
Albumin (g/L)
C-Reactive Protein
(mg/L)
Hemoglobin (g/L)
PTH (pmol/L)
‡

pvalue

r (95% CI)

0.30 (N/A) ‡
-0.21 (-0.74 to
0.48)
-0.61 (N/A) ‡

0.40
0.56

-0.17 (-0.72 to
0.51)
-0.33 (-0.79 to
0.37)
-0.19 (-0.73 to
0.50)
-0.34 (-0.80 to
0.36)

0.63

0.05
0.31

-0.51 (-0.86 to
0.17)
-0.22 (-0.75 to
0.48)
0.06 (-0.59 to
0.67)
0.05 (-0.60 to
0.66)

0.13

-0.12 (N/A) ‡

0.77

0.39 (N/A) ‡

0.35 (N/A) ‡

0.33

-0.49 (-0.85 to
0.20)
-0.35 (N/A) ‡

0.15

-0.33 (-0.80 to
0.38)
0.07 (N/A) ‡

0.35

0.35
0.59
0.33

0.33

0.84

Spearman’s correlation coefficient
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p-value

r (95% CI)

0.66 (N/A) ‡
0.36 (-0.35 to
0.80)
0.00 (N/A) ‡

0.06

Tibial [Na+]
(mmol/L)

-0.08 (N/A) ‡
0.11 (-0.56 to
0.69)
0.25 (N/A) ‡

0.84
0.77

-0.36 (-0.81 to
0.35)
0.06 (-0.59 to
0.66)
0.17 (-0.52 to
0.72)
-0.11 (-0.56 to
0.69)

0.30

0.30

0.42 (N/A) ‡

0.26

0.39 (N/A) ‡

0.27

0.29 (N/A) ‡

0.42

-0.65 (-0.91 to 0.04)
-0.15 (N/A) ‡

0.04

-0.45 (-0.84 to
0.26)
0.09 (N/A) ‡

0.20

-0.34 (-0.80 to
0.37)
0.13 (N/A) ‡

0.34

-0.14 (-0.71 to
0.54)
0.68 (N/A) ‡

0.70

1.00

0.55
0.86
0.90

0.68

0.71

0.48

0.87
0.64
0.74

0.81

0.04

Table 2.8 shows the results of the statistically significant correlations from Tables 2.4-2.7 after
Bonferroni correction. Only BMI vs Skin [Na+] (Control), Age vs Soleus [Na+] (Control) and
Albumin vs Soleus [Na+] (HD) remained statistically significant after correction.
Table 2.8: Bonferroni correction for significant findings.

pvalue

Bonferroni’s

𝛼

Significance

0.0027

0.0045

Yes

0.0331

0.0045

No

0.0026

0.0045

Yes

0.0211

0.0045

No

0.0073

0.0045

No

0.0379

0.0038

No

0.0027

0.0038

Yes

-0.78 (-0.94 to
-0.32) ‡

0.0063

0.0038

No

Hemoglobin

-0.76 (-0.93 to
-0.32)‡

0.0052

0.0038

No

PTH

0.68 (N/A) ‡

0.0355

0.0038

No

Group

Dependent variable

Independent
variable

Controls

Skin [Na+]

BMI

Controls

Skin [Na+]

Age

Controls

Soleus [Na+]

Age

CKD

Soleus [Na+]

Hemoglobin

CKD

Tibial [Na+]

Hemoglobin

HD

Skin [Na+]

Hemoglobin

HD

Soleus [Na+]

Albumin

HD

Tibial [Na+]

Albumin

HD

Tibial [Na+]

PD

Tibial [Na+]

r (95% CI)
0.83 (0.43 to
0.96)
0.67 (0.07 to
0.91)
0.84 (0.43 to
0.96)
-0.65 (-0.89 to
-0.13)
-0.73 (-0.91 to
-0.26)
-0.60 (-0.87 to
-0.04)
-0.81 (-0.95 to
-0.40)

Figures 2.5, 2.6 and 2.7 show the main correlations of tissue [Na+] with clinical biomarkers. Figure
2.5 shows a negative, statistically significant correlation between eGFR and soleus and tibial [Na+]
after merging the Control and CKD groups.

Figure 2.5: Correlation analysis for the relationship between eGFR and Skin, Soleus and Tibial [Na+] (Panels A, B and C
respectively) in both Control and CKD group.
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Figure 2.6 shows that hemoglobin had the strongest correlation with tibial [Na+] in both CKD
(Panel C) and HD group (Panel D).

Figure 2.6: Correlation analysis for the relationship between Hemoglobin and Soleus [Na+] (Panels A, B), and Tibial [Na+]
(Panel C, D) in CKD and HD patients.
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Figure 2.7 shows that albumin exhibits a strong, negative linear correlation with soleus [Na+] in
the HD group.

Figure 2.7: Correlation analysis for the relationship between serum Albumin and Soleus [Na+] in HD patients.

Interobserver Variability
The intraclass correlation coefficients for single measures were 0.98 (p<0.0001) for the skin [Na+],
0.96 (p<0.0001) for the soleus [Na+] and 0.88 (p<0.0001) for the tibial [Na+]. An intraclass
correlation coefficient value of > 0.90 was considered excellent, and a value between 0.75 and
0.90 was considered good.
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2.4 Discussion
In this study, we report several novel aspects of tissue sodium deposition measured by 23Na MRI
of the lower leg. Firstly, we systematically compared tissue [Na+] between CKD, HD and PD
patients, representing the broad clinical spectrum of CKD. Secondly, we described tissue [Na+] in
the tibial bone of CKD and dialysis patients. Finally, we showed preliminary correlations between
tissue [Na+], demographics, anthropometrics and clinical biomarkers of renal function and
inflammation.
We observed that tissue [Na+] increases progressively in all measured compartments across the
whole kidney disease spectrum, with HD and PD patients demonstrating the highest tissue [Na+].
Although not statistically significant, healthy controls were younger when compared to CKD, HD
and PD patients. This needs to be taken into account as a potential confounder, as age plays a major
role in determining skin and muscle [Na+], as pointed out by several studies.13–15
Many other factors need to be taken into account when analyzing the differences between groups;
we have shown a role of sex, diabetes and diuretic use (Table S2). In this respect, patients showing
peripheral and subcutaneous edema were outliers and were excluded from the subgroup analysis.
In healthy controls and CKD patients, we observed a negative correlation between eGFR and both
soleus and tibial [Na+], suggesting that a progressive impairment in kidney function may result in
increased tissue [Na+].

The current status of the clinical knowledge of sodium metabolism in CKD and renal replacement
therapy has been recently reviewed in detail by Canaud et al.16 Historically, Titze’s experimental
findings in rat models have clarified many of the mechanisms underlying sodium deposition in
different tissues. The skin has been identified as a major site of extracellular, osmotically inactive
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sodium storage in both rodents and humans.5,9 In this compartment, the osmotic effects of sodium
are inactivated by negatively charged proteoglycans.6 Resident macrophages are able to sense local
[Na+], and regulate skin sodium clearance by controlling lymphangiogenesis through VEGF-C
secretion.17 In the muscles, sodium is stored largely intracellularly via a mechanism mediated by
mineralcorticoid receptors, and exchanged with intracellular potassium to maintain intracellular
osmolarity.18 The skeleton is another essential site of tissue sodium deposition, as suggested by
Titze et al in 2002.19 To our knowledge, however, the underlying mechanisms controlling this have
not been elucidated.

Studies describing tissue sodium deposition and its effects in humans with CKD are limited and
are dependent on direct sodium visualization with leg 23Na MRI. Schneider et al reported a positive
correlation between skin [Na+] and left ventricular mass, independent of BP and overhydration (by
bioimpedance spectroscopy).20 Dahlmann and co-workers reported higher skin and muscle [Na+]
in HD patients over 60 years, compared to age-matched healthy controls.15 In addition, lower
plasma levels of VEGF-C were observed in HD patients compared to controls, suggesting that HD
patients have an impaired skin sodium clearance. Kopp et al also reported an increased skin and
muscle [Na+] in type 2 diabetes HD patients compared to non-diabetic HD patients, suggesting a
role of insulin resistance in tissue sodium deposition.21 Recent studies have also reported that skin
and muscle sodium can be mobilized by clinical interventions, namely diuretic therapy in acute
heart failure22 and ultrafiltration in HD patients.15
A significant finding of this study is that increased muscle [Na+] were associated with a significant
reduction in serum albumin in HD patients. Serum albumin is a strong independent predictor of
mortality in patients on renal replacement therapy.23,24 Although the mechanisms of
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hypoalbuminemia in these patients are still largely unclear,25 we speculate whether elevated tissue
[Na+] (directly or via inflammation) could impair albumin synthesis, in patients on renal
replacement therapy.

A potential association between increased tissue [Na+] and anemia was also observed in CKD and
HD patients. These associations may point out a role of sodium in regulating iron metabolism
and/or erythropoiesis through inflammatory pathways, leading to erythropoiesis-stimulating agent
resistance in patients on renal replacement therapy.26,27 Although these findings failed to reach
statistical significance after correcting for type 1 error, the novelty of this findings likely deserves
further investigation in future studies.

In this study, we described several associations of tibial [Na+] with demographics, anthropometrics
and other clinical biomarkers. These findings suggest that

23

Na MRI may expand our

understanding of sodium metabolism in relationship to mineral bone disease associated with CKD.
To our knowledge, however, 23Na MRI-based bone [Na+] measurements currently lack a validation
against gold standard techniques (such as ashing, as reported by Kopp et al).13

23

Na MRI allows direct visualization and quantification of tissue sodium deposition, non-

invasively and with high reproducibility. This makes it extremely interesting in the nephrology
setting due to the lack of other reliable sodium quantification techniques,8,9 and will likely spark
new interest to monitor the effects of interventions on dietary sodium and sodium removal
techniques.
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In the wake of our results, we anticipate that future studies will expand in four different directions:
[1] delineating the clinical associations of

23

Na MRI-based tissue [Na+] in CKD and renal

replacement therapy patients with appropriately powered observational studies; [2] validating
tissue [Na+] with clinical outcomes; [3] perfecting and optimizing sodium removal strategies; [4]
designing randomized controlled trials to test the efficacy of sodium removal.

Several limitations need to be acknowledged in this study: 23Na MRI remains at present confined
to the research environment, and its clinical availability is limited by the cost and the technical
expertise required for its development. This imaging technique is inherently burdened by low
resolution (voxel size: 3x3x30 mm), resulting in partial volume effects and affecting the signal
recorded from the regions of interest (e.g. skin, edema). The cross-sectional design of this study
does not allow us to infer causality from correlations. Our subject sample was small; as shown by
our sample size calculation, our study was underpowered to show differences in tissue [Na+]
between controls and CKD patients. Other subgroup analyses we performed likely require bigger
sample sizes as well. At present the measurement of tibial [Na+] with 23Na MRI lacks a clinical
validation and its role remains highly speculative.
The relationship between tissue [Na+] and BP has been the subject of several 23Na MRI studies.
However, office BP and 24-hour ambulatory BP measurements were not consistently available in
this study. Dietary sodium intake is likely a major determinant of tissue sodium deposition,
detailed assessment of this though was beyond the scope of this initial study.

Conclusions
This study further reinforces and expands the previously recognized role of sodium as a critical
uremic toxin, accumulating in patients with reduced kidney function. Tissue [Na+] by leg
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23

Na

MRI increase progressively across the CKD spectrum, with patients on renal replacement therapy
having significantly higher tissue [Na+] compared to healthy controls. Tissue [Na+] were correlated
with well-established clinical biomarkers, suggesting several potential adverse metabolic effects
of tissue sodium deposition in CKD, HD and PD patients, and deserve further investigation. 23Na
MRI allows noninvasive, reproducible tissue sodium quantification: its application may help
clinicians guide diagnostic and therapeutic decision-making in CKD and renal replacement therapy
patients.
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Chapter 3
Effects of pediatric chronic kidney disease and its etiology on leg tissue sodium
concentration.
In this study, we moved from the adult to the pediatric CKD population. Taking advantage of the
lower comorbidity burden in the pediatric population compared with adults, we hypothesized that
different etiologies of pediatric kidney disease would be associated with different tissue [Na+].

A version of this chapter has been published in the journal “Pediatric Nephrology” Salerno FR,
Akbari A, Lemoine S, Scholl TJ, McIntyre CW, Filler G. Effects of pediatric chronic kidney disease
and its etiology on tissue [Na+]: a pilot study. Pediatr Nephrol. 2022 Jun 2. doi: 10.1007/s00467022-05600-7. Epub ahead of print. PMID: 35655040. This article is available under the terms of
the Creative Commons Attribution License.

3.1 Introduction
The ECV compartment is closely associated with total body sodium (Na+) content in humans1,2,
and its accurate assessment is notably difficult in clinical practice. Changes in ECV status, and
ECV expansion in particular, are associated with significant morbidity and mortality in patients
with CKD3,4. Sodium-23 magnetic resonance imaging (23Na MRI) allows the non-invasive
assessment of tissue [Na+] to estimate Na+ status and ECV status5. Furthermore, osmotically
inactive Na+ deposits have been suggested to influence tissue [Na+], adding an additional level of
complexity to the clinical estimate of total body Na+ 6,7. The clinical relevance of tissue [Na+] is
becoming increasingly recognized in the CKD setting, as skin [Na+] accumulation has been
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associated with left ventricular hypertrophy in non-dialysis CKD8, potentially leading to adverse
outcomes in patients on dialysis9. Although there is evidence for increased tissue [Na+] in CKD
adult patients compared with healthy individuals10,11, actual tissue [Na+] based on CKD etiology
has not been demonstrated in children and adolescents to date. Indeed, this measure is also of
interest in the pediatric CKD population, where kidney Na+ handling can be widely impaired due
to both acquired and inherited disease mechanisms. In fact, inherited tubular disorders (e.g. Bartter,
Gitelman and Fanconi syndrome) are associated with kidney Na+ wasting, whereas proteinuric
glomerular diseases and nephrotic syndrome (e.g. minimal change disease, focal segmental
glomerulosclerosis) are associated with kidney Na+ retention12,13. Furthermore, the pediatric
setting offers an ideal opportunity to explore the impact of specific CKD disorders on tissue [Na+],
due to the lower prevalence of metabolic and cardiovascular disease compared with the adult CKD
population.
In this study, we hypothesized that CKD in children and adolescents is associated with altered
tissue [Na+] in relation to healthy controls and to the etiology of CKD. In a cross-sectional, casecontrol study, we compared tissue [Na+] in children and adolescents with CKD against healthy
controls and investigated the associations of tissue [Na+] with clinical biomarkers of kidney
function.

3.2 Materials and Methods
Study design
We performed a cross-sectional, case-control exploratory study. Study participants underwent an
investigational visit consisting of a research imaging session (1H and 23Na MRI of either the right
or left leg), demographic and clinical data were collected, and blood biochemistry was measured.
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The study received approval from the Western University Human Research Ethics Board (number:
108765) and was conducted in compliance with the Declaration of Helsinki and all applicable
regulatory requirements. This study was registered (ClinicalTrials.gov Identifier: NCT03004547)
on December 29th, 2016.

Study participants
Study patients were recruited from the London Health Sciences Centre, London, ON, Canada from
March 2018 to June 2021. For consenting minors, a written assent was obtained in addition to a
written informed consent signed by their legal guardians. Adult (age ≥ 18) study participants
provided written informed consent. Healthy children and adolescents, as well as adults, had no
history of kidney, heart and liver disease or edema. Pediatric CKD patients had a clinical diagnosis
of CKD according to current clinical guidelines (augmented by histological assessment in some
patients), were kidney allograft recipients, or were currently receiving kidney replacement therapy.
Potential study candidates were excluded if they had contraindications to MRI or did not consent
to the study.

Magnetic Resonance Imaging and Image Analysis
All MRI data were acquired using a multinuclear-capable, 3.0-Tesla GE MRI scanner (Discovery
MR750, General Electric Healthcare, Milwaukee, WI, USA). To acquire 23Na spin density images,
subjects were positioned in the magnet bore in the supine position, with the thickest part of their
right or left calf muscle at the center of a custom-made 23Na birdcage radiofrequency coil (~20 cm
diameter by 21.5 cm long). Calibration vials with increasing saline concentrations were placed in
the RF coil adjacent to the subjects’ shins. A single-slice
90

23

Na MR image was obtained with a

radial k-space acquisition pulse sequence (Density-Adapted 2D Projection Reconstruction)14, with
the following parameters: slice-selective radiofrequency pulse; flip angle 90°; repetition time/echo
time: 100/1.2 msec; number of signals averages: 100; slice thickness: 3 cm and isotropic field of
view/resolution: 18 cm/0.3 cm2; total acquisition time: ~30 minutes.
During the same imaging session, additional axial 1H MR images were acquired using a standard
(Spoiled Gradient-Recalled Echo) pulse sequence to identify and delineate the relevant anatomical
structures.
23

Na concentration maps were generated using custom software developed within MATLAB,

version 9.6.0 – R2019a (The MathWorks Inc., Natick, Massachusetts) with additional open-source
code from the Michigan Image Reconstruction Toolbox (Jeffery A. Fessler, “Michigan
Reconstruction Toolbox”, web.eecs.umich.edu/~fessler/code/). Regions of interest for the whole
leg, the skin and the soleus muscle were manually segmented after superimposing 1H and

23

Na

images, as detailed previously15.

Laboratory Analysis
Blood samples were collected from study participants, processed, and analyzed in a central tertiary
care hospital laboratory (London Health Sciences Centre, London, Ontario, Canada) for routine
clinical biomarkers. Estimated glomerular filtration rate (eGFR) was calculated using the
creatinine-based bedside Schwartz formula16 and the cystatin C-based equation17. The normalized
urinary [Na+] to urinary creatinine concentration (uNa+/uCreat) from morning spot urine samples
was used to evaluate potential kidney sodium wasting and 24-hour urinary sodium excretion.
Urinary protein-to-creatinine ratio (uPCR) was used to estimate 24-hour urinary protein excretion
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and was calculated according to the 2012 CKD Kidney Disease: Improving Global Outcomes
(KDIGO) clinical guidelines18.

Statistical Analysis
Statistical analysis was performed using GraphPad Prism version 9.0.0 (GraphPad Software, San
Diego, CA, USA; www.graphpad.com) and SPSS Version 27.0 (IBM Corp. Released 2020. IBM
SPSS Statistics for MacIntosh, Armonk, NY: IBM Corp). Normality was assessed using the
Shapiro–Wilk test. Continuous variables were tabled as mean ± standard deviation (SD) if
normally distributed and as median (25th percentile, 75th percentile), if highly skewed. Highly
skewed data sets were transformed using their natural logarithm for analyses. Kruskal-Wallis oneway analysis of variance test was used to compare tissue [Na+] between healthy children and
pediatric CKD patients; Dunn’s posthoc test was used to compare the individual groups. Tissue
[Na+] values in pediatric CKD patients were then stratified by etiology and individually compared
against healthy children’s by computing their Z-scores, based on the healthy children’s mean tissue
[Na+] and SD. An absolute Z-score greater than 1.96 was deemed to deviate significantly from the
healthy children’s mean. Univariate associations were computed between tissue [Na+],
demographics, anthropometry and clinical biomarkers of kidney function using Pearson’s productmoment correlation. For each dependent variable, p-values were corrected for family-wise error
using the Bonferroni-Holm correction. An α<0.05 was considered statistically significant.
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3.3 Results
Table 3.1 summarizes the demographics, anthropometry, and tissue [Na+] values relative to the
study sample. No significant differences in demographics and anthropometrics were found
between healthy controls and CKD patients.

Table 3.1: Demographics, anthropometry and tissue [Na+] according to study group.

Variable

Age (years)
Sex (M/F)
Weight (kg)
Height (m)
BMI (kg/m2)

Healthy Adults (n=19)

Healthy Children
and Adolescents
(n=17)

CKD
Patients
(n=19)

57.4 ± 15.8
10/9
69.9 ± 11.5
1.67 ± 7.72
24.9 ± 2.8

11.5 ± 3.5
9/8
41.1 ± 13.8
1.50 ± 0.16
17.8 ± 2.5

12.0 ± 3.6
10/9
45.7 ± 25.1
1.46 ± 0.22
20.0 ± 6.2

20.1 ± 3.5
20.2 ± 6.3
22.0 ± 2.9

16.3 ± 1.6
12.8 ± 2.5
18.5 ± 1.8

17.9 ± 6.2
15.0 ± 6.4
19.8 ± 6.5

23

Na MRI

Whole leg [Na+]
Skin [Na+]
Muscle [Na+]

Data are presented as Mean ± SD or ratios (Sex). BMI: body mass index; CKD: chronic kidney
disease; MRI: magnetic resonance imaging; SD: standard deviation.

Table 3.2 summarizes the clinical and biochemistry features of the CKD sample. Six (31%) CKD
patients qualified as CKD KDIGO stage 3a. Ten (53%) CKD cases were primarily due to
glomerular disease, the rest to inherited tubulo-interstitial kidney disease (six, 31%), CAKUT
(two, 11%) and primary calcineurin inhibitor (CNI) toxicity (one, 5%). Three patients (16%) were
kidney transplant recipients receiving standard immune-suppressant regimens. One was receiving
thrice-weekly HD and one was receiving continuous ambulatory PD.
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Table 3.2: Clinical features, blood and urine biochemistry of the CKD patient group.

CKD Stages

Statistics

1
2
3a
3b
4
5

3 (16%)
3 (16%)
6 (31%)
1 (5%)
3 (16%)
1 (5%)

5d

2 (11%)

Primary Kidney Disease Etiology
Glomerular Disease
Tubulo-Interstitial (Inherited)
CAKUT/Reflux Nephropathy
CNI Toxicity
Heart Transplant

10 (53%)
6 (32%)
2 (11%)
1 (5%)
1 (5%)

HD
Kidney Transplant
PD

5 (26%)
1 (5%)
3 (16%)
1 (5%)

Comorbidities
Other Organ Transplants (heart, liver)
Hypertension
Diabetes Mellitus

2 (11%)
9 (47%)
2 (11%)

Kidney Replacement Therapy

Medications
ACEi-ARB
Beta-Blocker
Calcium Channel Blocker
Loop Diuretic

10 (53%)
1 (5%)
9 (47%)
6 (32%)

Immune Suppressant Medications
Steroids
CNI
mTORi

5 (26%)
5 (26%)
1 (5%)

Antimetabolite

5 (26%)
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eGFR Schwartz (ml/min/1.73m2)
eGFR Cystatin (ml/min/1.73m2)
Urine creatinine (mg/L)
Proteinuria (mg/L) (median (IQR))
uPCR (mg/g) (median (IQR))
Urine [Na+]/uCreat (mmol/mmol)

55 ± 42
43 ± 25
758 ± 382
300 (80-2,185)
422 (121-3,420)
21.8 ± 17.2

Serum creatinine (umol/L)
Serum cystatin C (mg/L)
Serum urea (mmol/L)

198.6 ± 224.9
2.55 ± 1.90
11.3 ± 5.9

Serum albumin (g/L)
Serum glucose (mmol/L)
Serum [Na+] (mmol/L)
Serum [K+] (mmol/L)
Serum [HCO3-] (mmol/L)
Blood hemoglobin (g/L)

40.9 ± 8.4
6.5 ± 2.7
138.9 ± 2.5
4.3 ± 0.7
24.8 ± 2.9
118.0 ± 14.4

Data are expressed as %, mean ± SD and median (IQR) as appropriate.
[HCO3-]: bicarbonate concentration; [K+]: potassium concentration; [Na+]: Sodium concentration;
ACEi/ARB: angiotensin-converting enzyme inhibitor/ angiotensin receptor blocker; CAKUT:
congenital anomalies of kidney and urinary tract; CKD: chronic kidney disease; CNI: calcineurin
inhibitor; eGFR: estimated glomerular filtration rate; HD: hemodialysis; IQR: interquartile range;
mTORi: mammalian Target Of Rapamycin inhibitor; PD: peritoneal dialysis; SD: standard
deviation; uCreat: urinary creatinine concentration; uPCR: urinary protein-to-creatinine ratio.

Tissue [Na+] in Healthy Controls vs. CKD Patients
Healthy adults had significantly higher tissue [Na+] compared with both healthy children and
adolescents (Table 3.1).
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After comparing the healthy children and adolescents with CKD patients, no statistically
significant differences in whole leg, skin, and muscle [Na+] were observed (Figure 3.1).

Figure 3.1: Tissue [Na+] according to the three groups: in healthy children and adolescents vs CKD patients vs healthy adults.
(A: Whole leg [Na+]; B: Skin [Na+]; C: Muscle [Na+])

*: p<0.05; **: p<0.01; ***: p<0.001

However, a large variability in tissue [Na+] values was observed among the patients with CKD,
suggesting a more detailed investigation on a case-by-case analysis was warranted. Tissue [Na+]
Z-scores were therefore computed for each CKD patient using the healthy children and adolescents
group data to compare individual CKD patients to the reference healthy sample.
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Tissue [Na+] According to CKD Etiology
Table 3.3 summarizes individual CKD patient kidney function, tissue [Na+] raw values and Zscores. Elevated whole-leg [Na+] Z-scores were found among patients with non-hemolytic uremic
syndrome (HUS) glomerular disease and native kidneys (ID: 1, 3, 9, 18), and one kidney transplant
recipient due to atypical HUS (ID: 5). Reduced whole-leg [Na+] Z-scores were found in patients
with inherited tubular disorders (ID 12, idiopathic Fanconi syndrome, and ID 17, idiopathic
combined proximal and distal renal tubular acidosis), and in patients with CNI toxicity (ID 11,
heart transplant recipient, and ID 13, kidney transplant recipient due to atypical HUS).
Skin [Na+] and muscle [Na+] were similarly increased in three glomerular disease patients (ID: 1,
5, 18, and 1, 9, 18, respectively). Only 1/19 (5%) CKD patient had a skin [Na+] Z-score <-1.96
(ID 17), and 3/19 (16%) had muscle [Na+] Z-scores <-1.96 (ID 12, 13, 17), as detailed in Table
3.3.

Table 3.3: Individual demographics, clinical features and tissue [Na+] of the CKD patient group.

eGFRCyst
(ml/min/1.7
3 m 2)

uPCR
(mg/g
)

uNa+/uCreat
(mmol/mmo
l)

Wholeleg
[Na+]
mmol/
L (Zscore)
30.8
(8.93)
15.1
(-0.71)
19.8
(2.16)

Skin
[Na+]
mmol/
L (Zscore)

Muscl
e [Na+]
mmol/
L (Zscore)

27.8
(5.96)
11.5
(-0.52)
17.1
(1.70)

33.7
(8.52)
18.8
(0.17)
18.6
(0.08)

ID

Ag
e

Se
x

Kidney Disease
Etiology

eGFRSchw
(ml/min/1.7
3 m 2)

1

6

M

FSGS (NPHS1
mutation)

16

20

14,42
8

29

2

13

F

Typical HUS

51

46

503

16

3

13

M

FSGS

22

23

1,354

12

16

23

396

10

17.0
(0.44)

14.5
(0.66)

17.7
(-0.42)

58

44

500

19

21.7
(3.35)

25.4
(4.98)

20.8
(1.28)

63

37

65

7

16.2
(-0.04)

12.5
(-0.10)

18.6
(0.07)

4

14

F

5

14

M

6

10

M

Recurrent UTI,
neurogenic
bladder (spina
bifida)
Kidney transplant
(atypical HUS)
Tubulo-interstitial
kidney disease
due to
methylmalonic
acidemia, liver
transplantation

97

7

16

M

Renal coloboma
syndrome (PAX2
mutation)

28

28

6,661

20

8

8

F

Atypical HUS

28

25

4,109

26

9

17

F

10

17

6,532

4

10

6

F

57

50

118

11

9

M

79

68

12

14

F

68

13

14

M

14

14

M

15

17

F

16

11

M

17

6

M

18

14

F

19

12

F

Immune-complex
MPGN
Unilateral kidney
agenesis, kidney
infarction
CNI toxicity
(heart
transplantation)
Idiopathic
Fanconi
Syndrome
Kidney transplant
(atypical HUS),
Secondary CNI
toxicity
Kidney transplant
(Alport
Syndrome)
Autosomal
dominant
tubulointerstitial
kidney disease
(UMOD
mutation)
Hypophosphate
mic Rickets with
Hypercalciuria
(SLC34A3
mutation)
Idiopathic
Combined
Proximal and
Distal Renal
Tubular Acidosis
(type 3)
FSGS (currently
on HD, with
residual urinary
volume)
FSGS (currently
on PD, without
residual urinary
volume)

15.6
(-0.42)

14.3
(0.60)

18.5
(0.01)

16.4
(0.09)
20.4
(2.55)

8.6
(-1.66)
12.7
(-0.06)

19.5
(0.57)
23.3
(2.71)

35

13.6
(-1.63)

8.1
(-1.86)

19.0
(0.29)

88

21

12.3
(-2.43)

9.2
(-1.42)

16.1
(-1.33)

55

449

16

12.0
(-2.62)

10.7
(-0.84)

14.6
(-2.16)

116

40

245

25

12.8
(-2.14)

13.8
(0.41)

10.3
(-4.56)

56

46

61

6

17.5
(0.78)

15.6
(1.13)

21.1
(1.49)

40

47

38

7

16.8
(0.36)

15.3
(0.99)

18.3
(-0.08)

156

38

131

21

18.4
(1.31)

14.5
(0.68)

21.2
(1.50)

128

131

157

78

11.6
(-2.89)

6.9
(-2.33)

12.8
(-3.20)

-

-

-

-

36.2
(12.21)

30.4
(6.97)

38.2
(11.00)

-

-

-

-

15.7
(-0.33)

16.6
(1.50)

15.4
(-1.69)

Tissue [Na+] and Z-scores calculated from healthy children and adolescents are reported in
parenthesis.
CNI: calcineurin inhibitor; eGFR: estimated glomerular filtration rate; FSGS: focal segmental
glomerulosclerosis; HD: hemodialysis; HUS: hemolytic-uremic syndrome; NPHS1: nephrin gene;
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PAX2: paired box gene 2; PD: peritoneal dialysis; SLC34A3: sodium-phosphate cotransporter
gene; UMOD: uromodulin; uNa+/uCreat: urinary [Na+] to urinary creatinine ratio; uPCR: urinary
protein-to-creatinine ratio; UTI: urinary tract infection.

Correlations
Correlations between variables are represented in Table 3.4.
Table 3.4: Associations between demographics, anthropometry and clinical variables with tissue [Na +] in healthy children and
adolescents and CKD patients.

Whole leg [Na+]

Variable

r (95% CI)
Healthy Children,
Adolescents and
Adults
Age
Healthy Children and
Adolescents
Age
BMI
CKD Patients
Age
BMI
eGFR Cystatin
eGFR Schwartz
Serum Albumin
uNa+/UCreat
uPCR

Adjusted p

Skin [Na+]
r (95% CI)

Adjusted p

Muscle [Na+]
r (95% CI)

Adjusted p

0.776 (0.600;
0.880)

<0.001

0.734 (0.534;
0.856)

<0.001

0.727 (0.524;
0.852)

<0.001

-0.479 (-0.780;
0.003)
-0.073 (-0.535;
0.422)

0.10

0.084 (-0.414;
0.542)
0.224 (-0.288;
0.636)

0.78

-0.118 (-0.567;
0.384)
-0.006 (-0.485;
0.476)

>0.99

0.071 (-0.396;
0.509)
-0.088 (-0.521;
0.382)
-0.432 (-0.741;
0.028)
-0.323 (-0.678;
0.153)
-0.658 (-0.856; 0.291)
-0.249 (-0.652;
0.263)
0.736 (0.394;
0.899)

>0.99

0.211 (-0.269;
0.607)
0.030 (-0.430;
0.478)
-0.431 (-0.740;
0.028)
-0.282 (-0.653;
0.197)
-0.596 (-0.826; 0.194)
-0.281 (-0.671;
0.231)
0.509 (0.037;
0.795)

>0.99

-0.030 (-0.478;
0.430)
0.001 (-0.453;
0.455)
-0.356 (-0.697;
0.117)
-0.324 (-0.678;
0.153)
-0.613 (-0.835; 0.220)
-0.237 (-0.645;
0.275)
0.764 (0.448;
0.910)

>0.99

0.78

>0.99
0.33
0.71
<0.05
0.34
<0.001

0.78

>0.99
0.33
0.96
<0.05
0.28
<0.05

>0.99

>0.99
0.68
0.71
<0.05
0.36
<0.001

Pearson correlation was used to compute the relationship. BMI: body mass index; CKD: chronic
kidney disease; eGFR: estimated glomerular filtration rate; uNa+/uCreat: urinary sodium-tocreatinine ratio; uPCR: urinary protein-to-creatinine ratio.
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Among healthy children, adolescents and adults, age was strongly and positively associated with
all tissue [Na+] (Figure 3.2).

Figure 3.2: Scatterplots showing the relationship between age with whole leg [Na +] (Panel A), skin [Na+] (Panel B) and muscle
[Na+] (Panel C) in healthy children, adolescents and adults (n=36).

Among CKD patients, serum albumin was negatively associated with all tissue [Na+] measures
(whole leg [Na+] r=-0.658, p<0.01; skin [Na+] r=-0.596, p<0.01; muscle [Na+] r=-0.613, p<0.01)
(Figure 3.3, panels A, B and C).
Likewise, uPCR was positively associated with all tissue [Na+] measures (whole leg
[Na+],r=0.736, p<0.001, skin [Na+], r=0.501, p<0.05, muscle [Na+], r=0.764, p<0.001)) (Figure
3.3, panels D, E and F). No other significant associations were observed.

Figure 3.3: Scatterplots showing the relationship between serum albumin (Panels A-C) and uPCR (Panels D-F) with tissue [Na+]
in pediatric CKD patients (n=19).
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3.4 Discussion
This study provides early evidence that tissue [Na+] status in children and adolescents with CKD
does not follow a uniform pattern of increased tissue [Na+]. Healthy children and adolescents had
lower tissue [Na+] than healthy adults, and tissue [Na+] was positively correlated with age.
Furthermore, some patients with tubular disease demonstrated reduced tissue [Na+], while others
demonstrated tissue [Na+] retention when the underlying etiology was nephrotic syndrome. The
main findings of this study may be summarized as follows:
● No significant differences in tissue [Na+] were observed between healthy children and
adolescents and CKD patients, owing to the spectrum of [Na+] retention and wasting.
● All cases of nephrotic syndrome were associated with increased whole leg [Na+] compared
with healthy controls.
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● The severity of tissue [Na+] among CKD patients correlated with the degree of proteinuria and
hypoalbuminemia.

Tissue [Na+] is an emerging quantitative imaging biomarker in clinical nephrology.

23

Na MRI

offers the possibility of quantifying total body sodium and estimating the clinical ECV status, due
to the prevalent location of sodium in the extracellular space1,5,19,
CKD as a function of eGFR reduction was not associated with abnormal tissue [Na+] per se.
Indeed, we observed that non-tubular and non-proteinuric forms of CKD were not associated with
abnormal tissue [Na+]. This suggests that measures of glomerular filtration are of small relevance
in relation to Na+ metabolism and highlights the challenges of a correct assessment of [Na+]
balance in CKD. Recent evidence points out that sodium retention in CKD is mainly associated
with altered distal tubular function, as the final regulator of urinary sodium excretion20,21.
23

Na MRI measures the sodium signal within a unit of tissue volume including extracellular matrix

(high in sodium content), cellular mass and fat tissue (low in sodium content)5,19,22. Recently,
ultra-high field (9.4T) coupled with triple quantum filtering 23Na MRI pulse sequence was able to
visualize and differentiate free (dissolved in water) from bound sodium at the dermal skin level23.
The authors found that ~40% of skin sodium in healthy volunteers to be bound to
glycosaminoglycans, whereas this fraction significantly decreases in type 2 diabetes mellitus.
Furthermore, the authors found that 23Na MRI using ultrashort echo-time pulse sequences, such as
the one used in the present study, is unable to visualize the bound sodium fraction due to its faster
transverse signal decay properties, compared with free sodium. Therefore, 23Na MRI technology
we employed in this study likely underestimated tissue [Na+], measured only as free tissue [Na+],
primarily relating to the ECV.
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These findings may be useful to interpret current and recent findings. At present, little is known
of tissue [Na+] in healthy children and adolescents. In one report, muscle [Na+] was found to be
lower in obese, hypertensive adolescents, compared with obese normotensive and healthy
adolescents. No differences in skin [Na+] were found24. We did not observe a significant
association between age and tissue [Na+] among healthy children and adolescents, therefore we
cannot comment on the changes in tissue composition and [Na+] with physiological growth.
Rather, the increase in tissue [Na+] we observed occurred across the whole life cycle, possibly as
a function of declining cellular mass with aging: it has been reported that the progressive increase
in tissue [Na+] observed in aging adults reflects a change in tissue composition over time.5
Speculatively, an age-dependent decline in osmotically inactive tissue [Na+] binding capacity may
also result in increased tissue [Na+], due to the increased free tissue [Na+] over bound tissue [Na+],
as observed in patients with type 2 diabetes mellitus23.Importantly, we found that pediatric patients
with nephrotic syndrome were likely to display higher tissue [Na+] compared with healthy children
and adolescents, and that tissue [Na+] was significantly associated with the degree of proteinuria
and hypoalbuminemia. This agrees with recent studies showing that distal tubular sodium
reabsorption is a key mechanism for sodium retention in CKD. The main mechanism for sodium
retention in proteinuric kidney disorders has been associated with urinary plasminogen excretion:
plasminogen is converted to plasmin in the tubular lumen, which activates the epithelial Na+
channel (ENaC) located in the connecting tubules12. In the present study, this is supported by the
positive association between all measures of tissue [Na+] with uPCR.
On the other hand, salt-wasting syndrome is caused by a variety of inherited and acquired tubular
disorders generally of childhood onset, and is associated with ECV contraction25. We have shown
evidence of tissue [Na+] depletion in two cases of inherited tubular disorders – Fanconi syndrome
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and mixed (type 3) renal tubular acidosis26. Other more commonly known salt wasting tubular
disorders, such as Bartter and Gitelman syndromes, may conceivably show similar results but were
not included in the current study.
Furthermore, we found evidence of tissue [Na+] depletion in two solid organ transplant recipients
(heart and kidney, respectively) with CNI toxicity. This observation conflicts with published
evidence showing that the CNI tacrolimus is associated with sodium-chloride cotransporter (NCC)
upregulation and salt-sensitive hypertension in rats27. The nephrotoxicity of CNI is multifaceted
and dose-dependent; tubular dysfunction is a recognized component of CNI toxicity, as proximal
tubular vacuolization as well as impaired tubular electrolyte handling have been observed28.
Because we cannot exclude the influence of tubulointerstitial damage related to chronic allograft
rejection on tubular dysfunction, as suggested by previous authors29, as well as Na+ restriction and
other supportive therapies, the observed findings are of anecdotal value and should be interpreted
with caution.
Assessment of Na+ balance with

23

Na MRI in CKD patients is relevant, as ECV expansion,

regardless of the methodology used to assess it in adults with CKD, is associated with adverse
clinical outcomes3,4. In a recent publication from our group, skin [Na+] was associated with
increased mortality and major adverse cardiovascular events in adult patients on dialysis,
highlighting the toxic effects of ECV expansion30. Although direct evidence of adverse outcomes
is lacking in children, it is recognized that ECV expansion leads to progressive adverse
cardiovascular remodeling which may translate into a negative prognostic impact in early and late
adulthood31. It has been recently acknowledged that the toxicity of tissue Na+ may also be
associated to osmotically inactive deposits, particularly at the skin level8,32. Importantly, the
existence of such deposits was directly visualized in human skin using ultra-high field triple
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quantum filtering

23

Na MRI23. Sodium balance studies have shown potentially extremely large

increases in total body sodium as a result of increased dietary salt intake, without concomitant
ECV expansion33,34.
However,

23

Na MRI technology is unable to differentiate water-free from water-bound tissue

sodium. Future studies should compare 23Na MRI-based tissue [Na+] against validated measures
of ECV (e.g. bromide dilution, bioimpedance spectroscopy) and exchangeable sodium (e.g. 24Na
radioisotope dilution).
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Limitations
Several limitations must be acknowledged when interpreting the results from this study. This was
a pilot study, with a small and heterogeneous sample, as patient availability was limited due to the
single-center nature of this study. The reported findings are of anecdotal value and should be
interpreted with caution.
The effect of supportive (e.g., Na+ restriction, antihypertensive, or diuretic therapy) and immune
suppressant regimens (e.g., corticosteroids, CNI) might have affected kidney Na+ handling and
due to the cross-sectional nature of this study, may act as potential confounders when evaluating
the results. Urinary Na+ excretion was based on spot urine collection and indexed to urinary
creatinine excretion; this biomarker has been shown to be an unreliable estimator of sodium intake,
as sodium excretion varies throughout the day35. Additionally, it has been shown that 24-hour
urinary sodium excretion fluctuates around daily dietary Na+ intake in healthy individuals,
following weekly (circaseptan) aldosterone and cortisol excretion cycles36,37. The mechanisms of
urinary sodium excretion in CKD are less explored and likely differ from healthy individuals 21,
and are also likely to differ between different kidney disease etiologies. Urinary proteinase
(plasminogen/plasmin) levels were not measured in the present study; although albuminuria
severity has been shown to be positively associated with urinary protease levels in diabetic kidney
disease and other kidney disorders38. Urinary protease may conceivably provide additional
information on the relationship between tissue [Na+] and primary kidney Na+ retention in
proteinuric kidney disorders. Limitations linked to 23Na MRI must be acknowledged: 23Na signal
is the weighted average of Na+ contained in all tissues within a voxel (partial volume effect). This
is relevant as fat tissue, low in Na+, may act as a potential confounder. Furthermore, it has been
suggested that 23Na MRI technology such as the one used in this study may be able to detect signal
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from “free” sodium, dissolved in water. Therefore, osmotically inactive “bound” sodium, due to
its spin properties would not be detected23.

Conclusions
Children and adolescents with reduced GFR do not universally have increased tissue [Na+].
Depending on etiology, pediatric CKD may be associated with either normal, increased, or reduced
tissue [Na+], compared with healthy controls. Nephrotic syndrome may be associated with
increased tissue [Na+] due to kidney sodium retention and ECV expansion, whereas tubular
disorders may be associated with reduced tissue [Na+], suggesting ECV depletion due to kidney
Na+ wasting. These findings require confirmation in larger studies, focused on specific etiologies
in the pediatric CKD population.
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Chapter 4
Tissue Sodium and Cardiac Structure in Chronic Hemodialysis Patients
In this study, we investigated the relationship between tissue [Na+] and cardiac structure, in
patients receiving HD.

A version of this chapter has been submitted to the journal “Hemodialysis International” and is
currently under peer review (ID: HDI-22-0128).

4.1 Introduction
Patients requiring long term HD commonly display left ventricular hypertrophy (LVH) and
abnormal left ventricular (LV) geometry.1 LVH itself is common in the HD population, with a
prevalence from 44% to 64% within cardiac magnetic resonance imaging-based studies.2,3
Furthermore, aberrant LV morphology is well-recognized as an independent prognostic factor for
cardiovascular morbidity and mortality.4 LVH can be further characterized into concentric
hypertrophy (CH) or eccentric hypertrophy (EH), and each category has been associated with
differing severity of effect on cardiovascular outcomes.5
ECV expansion is associated with increased total body sodium, and this is reflected by increased
tissue [Na+] measured with sodium-23 magnetic resonance imaging (23Na MRI).6,7 ECV expansion
is considered a fundamental driver of left ventricular mass (LVM) in CKD and dialysis patients.8
In addition, Schneider et al recently showed that skin [Na+], as measured with 23Na MRI of the
leg, is a strong predictor of left LVM in CKD patients, suggesting that skin [Na+] may have adverse
effects on the cardiovascular system.9 This may also be related to the effects of osmotically inactive
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sodium deposits at the skin dermis level.9 We have recently shown that HD patients exhibit greater
tissue [Na+] compared with healthy individuals, and that skin [Na+] is associated with adverse
outcomes in these patients.10,11 At present, however, no data is currently available on the
relationship between tissue [Na+] and LV structure in HD patients: we hypothesized that wholeleg and skin [Na+] were associated with LVH and other markers of LV structure, such as enddiastolic volume and geometry.

4.2 Materials and Methods
Study participants underwent a single research visit on a non-HD day (during the short interdialytic
interval). This consisted of an imaging session, clinical data collection and collection of blood for
laboratory analysis. All study participants signed informed consent prior to study enrollment. The
study received approval from the Western University Human Research Ethics board and was
conducted in compliance with the Declaration of Helsinki and all applicable regulatory
requirements (ClinicalTrials.gov: NCT03004547).
Study patients were recruited between March 2018 to March 2020 from the London Health
Sciences Centre, London, ON, Canada, from a maintenance HD population established on a stable
HD prescription for at least three months. Potential study candidates were excluded if pregnant,
breastfeeding or intending pregnancy, unable to provide consent or had contraindications to MRI.
Participant information were extracted from digital chart and HD treatment chart review. HD
treatment information were collected relative to the HD session immediately prior and after the
study visit and averaged. Office BP was measured with a clinically validated oscillometric
automatic sphygmomanometer after five minutes of rest in a quiet room; three consecutive
measurements were collected and the average was recorded for analysis.
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Study participants underwent

23

Na MRI of the leg as previously described by our group.10 23Na

concentration maps were computed using saline calibration phantoms containing increasing
sodium chloride concentrations. Two regions of interest, delineating the whole leg and the whole
skin were delineated manually using Horos software v4.0.0 (Horosproject.org, Nimble Co LLC
d/b/a Purview, Annapolis, MD, USA), and the average signal intensity were reported as whole-leg
[Na+] and skin [Na+].
Echocardiography was performed by an experienced member of the research team on the day of
the visit, using a Vivid Q (GE Healthcare) ultrasound machine. All measurements were performed
offline on the EchoPAC Software (GE Healthcare), were repeated three times in consecutive heart
cycles and average measurements were reported for each individual participant. LVM was
calculated using the linear method from 2D parasternal long axis images and indexed to height 2.7
(LVMI) due to the high prevalence of obesity in the study population, as according to the current
American Society of Echocardiography (ASE) guidelines.12 LVH was defined as LVMI above
51.0 g/m2.7 regardless of sex, according to previously published literature.4 Relative wall thickness
(RWT) was calculated according to the formula: RWT = (2*posterior wall thickness at enddiastole)/(LV internal diameter at end-diastole). A cut-off RWT value >0.42 was considered
abnormal. LV geometry was classified into normal geometry (normal LVMI and RWT),
concentric remodeling (normal LVMI, increased RWT), eccentric hypertrophy (increased LVMI,
normal RWT) and concentric hypertrophy (increased LVMI and RWT), as defined by the ASE
guidelines.12 Left ventricular end-diastolic volume (LVEDV) and ejection fraction (LVEF) were
measured from standard apical four and two-chamber views, according to the Simpson biplane
method. LVEDV was indexed to body surface area (LVEDV/BSA).
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Sample Size Justification and Statistical Methods
To our knowledge, only one study has reported on correlation between LVM (using cardiac MRI)
and skin [Na+] in patients with CKD, with an r=0.56.9 Utilizing data from this study, we calculated
a minimum of 26 participants were required to detect an r=0.5 with alpha=0.05 and 80% power.
The analysis plan was primarily focused at detecting a statistically significant correlation between
LVMI and whole-leg and skin [Na+]; secondary analyses aimed at the exploring the correlation
between whole-leg and skin [Na+] with LVEDV and LVEF, and differences in whole-leg and skin
[Na+] according to LV geometry.
We presented data stratifying participants according to LVH status. Continuous variables were
presented as mean ± standard deviation (SD) or median (interquartile range, IQR) depending on
data distribution. Categorical variables are presented as ratio and percentages. Pearson correlation
was used to investigate the association between whole-leg and skin [Na+] and echocardiography
parameters of interest. Student’s t test for independent samples was used to compare continuous
variables between non-LVH and LVH groups. Kruskal-Wallis one-way analysis of variance
(ANOVA) with Dunn’s post hoc test was used to compare Skin [Na+] between LV geometry
groups. Statistical analysis was performed with GraphPad Prism v9.0.0 for Mac, GraphPad
Software, San Diego, CA USA (www.graphpad.com) and R v3.6.2, R Foundation for Statistical
Computing, Vienna, Austria. (https://www.R-project.org/).

4.3 Results
31 participants underwent the study procedures. One patient was excluded from analysis due to
significant motion artifacts during MRI that made it impossible to compute
maps.
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23

Na concentration

Table 4.1 summarizes the clinical information of the overall sample and after LVH stratification.

Table 4.1: Characteristics of the study sample, stratified by left ventricular hypertrophy.

Overall (n=30)

No LVH (n=12)

LVH (n=18)

17/13

6/6

11/7

Age (years)

66 ± 11

64 ± 12

66 ± 10

BMI (kg/m2)

31.8 ± 6.4

29.3 ± 5.9

33.5 ± 6.3

Residual Renal Volume (ml/24h)

273 ± 352

316 ± 378

244 ± 342

HD Vintage (months)

22.0 (11.3-32.5)

22.0 (16.5-30.3)

20.0 (11.3-32.5)

HD Treatment Time (h/week)

12.0 (10.5-12.0)

12.0 (10.5-12.0)

11.6 (10.5-12.0)

13/17

4/8

9/9

2.1 ± 0.9

2.1 ± 1.2

2.2 ± 0.8

137 (137-140)

137 (137-139)

139 (137-140)

Office SBP (mmHg)

132 ± 26

118 ± 23

142 ± 26

Office DBP (mmHg)

75 ± 13

73 ± 15

73 ± 15

Hypertension (%)

77%

58%

89%

Diabetes Mellitus (%)

67%

58%

72%

Ischemic Heart Disease (%)

40%

25%

50%

Congestive Heart Failure (%)

23%

8%

33%

Demographics & Anthropometrics
Sex (M/F)

HD Treatment Details

Vascular Access (AVF/Catheter)
Average Weight Gain (%)
[Na+]D (mmol/L)

Comorbidities

Medications
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ACEi-ARB (%)

23%

8%

33%

Beta Blocker (%)

47%

33%

56%

Calcium Channel Blocker (%)

43%

8%

67%

Diuretic (%)

40%

42%

39%

Hemoglobin (g/L)

111 ± 12

113 ± 13

111 ± 13

Serum Albumin (g/L)

40.6 ± 3.4

42.5 ± 3.5

39.4 ± 2.9

Serum CRP (mg/L)

11.1 ± 17.7

8.2± 6.7

13.0 ± 22.2

Serum PTH (pmol/L)

58.7 ± 36.3

59.5 ± 45.6

58.1 ± 30.0

137 ± 3

136 ± 3

137 ± 3

Laboratory

Serum Sodium (mmol/L)

[Na+]D: dialysate sodium concentration; ACEi: angiotensin converting enzyme inhibitor; ARB:
angiotensin receptor blocker; AVF: arterio-venous fistula; BMI: body mass index; BSA: body
surface area; CRP: c-reactive protein; DBP: diastolic BP; HD: hemodialysis; LVH: left ventricular
hypertrophy; PTH: parathyroid hormone; SBP: systolic BP.

Overall, 60% (n=18) of the study sample had LVH. Obesity was common in the study sample.
Patients with LVH had higher whole-leg [Na+] and skin [Na+] compared with patients without
LVH (whole-leg [Na+]: t(28)=2.53, p<0.05); skin [Na+]: t(28)=3.30, p<0.01). Of note, whole-leg
[Na+] and skin [Na+] were strongly correlated with one another (r=0.85). No significant differences
in other demographics, anthropometrics and biomarkers were observed.
Skin [Na+], whole-leg [Na+] and echocardiography measurements are detailed in Table 4.2.

Table 4.2: Imaging data, stratified by left ventricular hypertrophy.
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Overall (n=30)

No LVH (n=12)

LVH (n=18)

Skin [Na+] (mmol/L)

26.7 ± 9.7

20.5 ± 7.5

30.9 ± 9.6

Whole-leg [Na+] (mmol/L)

26.3 ± 6.7

23.3 ± 5.0

28.7 ± 6.7

IVSd (cm)

1.3 ± 0.2

1.1 ± 0.2

1.4 ± 0.2

LVEDd (cm)

5.0 ± 0.7

4.7 ± 0.6

5.2 ± 0.8

PWd (cm)

1.1 ± 0.2

1.0 ± 0.2

1.2 ± 0.2

LVEF (%)

55 ± 12

60 ± 6

52 ± 13

LVEDV (ml)

124 ± 41

102 ± 21

138 ± 45

61.3 ± 19.2

52.3 ± 7.1

67.3 ± 22.5

237 ± 71

173 ± 46

281 ± 47

LVMI (g/m2.7)

56.8 ± 16.7

40.9 ± 7.9

67.5 ± 12.4

RWT

0.46 ± 0.12

0.42 ± 0.10

0.49 ± 0.14

23

Na MRI

Echocardiography

LVEDV/BSA (ml/m2)
LVM (g)

BSA: body surface area; IVSd: end-diastolic interventricular septum thickness; LVEDd: left
ventricular end-diastolic diameter; LVEDV: left ventricular end-diastolic volume; LVEF: left
ventricular ejection fraction; LVESV: left ventricular end-systolic volume; LVM: left ventricular
mass; LVMI: left ventricular mass index (height2.7); MRI: magnetic resonance imaging; PWd: enddiastolic posterior wall thickness; RWT: relative wall thickness; Skin [Na+]: skin sodium-23
concentration; Whole-leg [Na+]: whole-leg sodium-23 concentration.

LVEF was largely preserved in the study sample, regardless of LVH status. Eight participants were
classified as having a normal geometry (NG), five concentric remodeling (CR), eleven concentric
hypertrophy (CH), six eccentric hypertrophy (EH), according to LVH status and RWT.
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Figure 4.1 shows the correlations between tissue [Na+] (skin and whole-leg), LVMI and
LVEDV/BSA; both skin [Na+] and whole-leg [Na+] were positively associated with greater LVMI
(Skin [Na+]: r=0.425, p<0.05; whole-leg [Na+]: r=0.480, p<0.05) and LVEDV/BSA (skin [Na+]:
r=0.494, p<0.01; whole-leg [Na+]: r= 0.447, p<0.05).
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Figure 4.1: Correlation between tissue [Na+] (skin, whole-leg [Na+]) with LVMI (A, B) and LVEDV/BSA (C, D), respectively.

LVEDV/BSA: left ventricular end-diastolic volume / body surface area; LVMI: left ventricular
mass index (height in m2.7).

Figure 4.2 shows the differences in skin and whole-leg [Na+] according to LVH status (panels
A,B) and LV geometry (panels C, D). Both skin and whole-leg [Na+] were significantly higher in
patients with LVH (skin [Na+]: 20.5±6.0 mmol/L vs 30.9±9.6 mmol/L, p<0.01; whole-leg [Na+]:
22.9±5.3 mmol/L vs 28.7±6.7 mmol/L, p<0.05). Conversely, only skin [Na+] was significantly
different across LV geometry categories (Kruskal-Wallis statistic=12.6, p<0.01; NG vs CH:
19.2±3.4 mmol/L vs 28.1±6.9 mmol/L, p<0.05; NG vs EH: 19.2±3.4 mmol/L vs 36.3±12.5
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mmol/L, p<0.01). A trend for increasing whole-leg [Na+] across LV geometry categories was
observed, although it failed to reach statistical significance (Kruskal-Wallis statistic=6.6, p=0.09).

Figure 4.2: Tissue [Na+] (skin, whole-leg [Na+]) according to LVH (A, B) and to LV geometry category (C, D), ordered by
known escalating influence on negative cardiovascular outcomes.

CH: concentric hypertrophy; CR: concentric remodeling; EH: eccentric hypertrophy; LVH: left
ventricular hypertrophy; NG: normal geometry. * = p<0.05; ** = p<0.01
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4.4 Discussion
The main finding of this study is that quantitative

23

Na MRI measures of tissue [Na+], namely

whole-leg and skin [Na+], are associated with greater LVMI, LVEDV/BSA and LVH in patients
receiving long-term HD.
ECV expansion is an increasingly recognized problem in the HD population and has been shown
to correlate with LVH as well as clinical outcomes.13 According to traditional Edelman physiology,
sodium is the main extracellular cation and an increase in total body sodium is a hallmark of ECV
expansion.14 Indeed, tissue [Na+] measured with 23Na MRI reflects tissue sodium content per unit
of volume, as a function of both extracellular and intracellular volume.6,7 Therefore, an increase in
tissue [Na+] will primarily reflect ECV expansion in the tissue volume of interest.
Furthermore, recent evidence suggests that humans are able to accumulate sodium independently
of water mainly at the dermal skin level, bound to negatively-charged glycosaminoglycans and
regulated by immune-mediated pathways.15,16 These findings have been recently confirmed
visually using ultra-high field triple quantum filtering 23Na MRI in ex vivo human skin samples
from healthy volunteers and patients with type 2 diabetes mellitus.17 In addition, the referenced
study suggested that 23Na MRI using ultra-short echo time (UTE) pulse sequences (such as the one
used in the present study) is incapable of detecting the signal from bound tissue sodium as a result
of rapid signal decay due to its interactions with the glycosaminoglycan matrix, and that tissue
[Na+] would essentially be a function of sodium dissolved in water.
The present findings are in line with the results reported by Schneider and co-workers: the authors
found a relationship between skin [Na+] and LVM in 99 non-dialysis CKD patients as measured
with cardiac MRI; in multiple regression modeling the relationship was independent of SBP and
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bioimpedance spectroscopy measures of fluid overload, which the authors attributed to water-free
skin sodium accumulation.9
The relationship between tissue [Na+] and LV dilation has not been reported before. We also report
for the first time that abnormal LV geometry, specifically CH and EH, traditionally associated
with poorer cardiovascular outcomes, is significantly associated with higher skin [Na+]. EH in
particular is associated with previous cardiac events, ECV expansion and increased risk of sudden
cardiac death, compared with CH.5
Hence, we suggest that increased tissue [Na+] as detected by

23

Na MRI in HD patients reflects

ECV expansion, as previously mentioned,6,7,17 and plays a significant role in determining LV
dilation and abnormal LV geometry.
Several therapeutic options have been shown to reduce skin [Na+], such as ultrafiltration and
diuretic therapies in several clinical settings.18–20 A recent publication from our group also suggests
that reducing the dialysate [Na+] was associated with lower skin [Na+], although it was not possible
to discriminate the underlying mechanisms.21 Recent trial findings may provide additional support
on the causal relationship between total body sodium and cardiac structure: indeed, improved ECV
management may explain the findings of the Frequent Hemodialysis Network Daily Trial, where
frequent daily HD was associated with improvements in LVM and LVEDV.22,23
From an imaging biomarker perspective, whole-leg [Na+] reflects [Na+] from all anatomical
structures in the leg (skin, muscles, blood vessels, skeletal bones), and its delineation does not
require high image resolution; conversely, skin [Na+] requires sufficient image resolution for the
region of interest to be delineated and avoid significant partial voluming effects. We show here
that both biomarkers are similarly related to structural echocardiography measures. This is likely
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due to both biomarkers measuring the signal from sodium dissolved in extracellular water, as
previously mentioned.17
Study limitations include a cross-sectional design, single-center experience and the use of
echocardiography, which is known to overestimate LVM compared to MRI;2 in addition, no
assessment of volume status was performed with bioimpedance spectroscopy – therefore it was
not possible to relate tissue [Na+] with other measures of ECV. The association between tissue
[Na+] and echocardiography measurements was not corrected for potential confounders. The
association between tissue [Na+] and LV geometry was exploratory, and its significance limited
by the small and uneven number of cases per group.
We conclude that tissue [Na+] is associated with worse cardiac structure and may be an important
mediator of cardiovascular outcomes in the HD population: this highlights the central role of ECV
expansion and sodium balance in HD. In this respect, 23Na MRI offers a quantifiable target to test
the effects of optimized sodium removal strategies on cardiovascular outcomes for future clinical
trials.
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Chapter 5
Outcomes and Predictors Associated with Skin Sodium Concentration in
Dialysis Patients
In this study, we investigated the clinical predictors of skin [Na+] as well as the relationship
between skin [Na+] with clinical outcomes in patients receiving HD and PD.

A version of this chapter has been published in the “Clinical Kidney Journal” Salerno FR, Akbari
A, Lemoine S, Filler G, Scholl TJ, McIntyre CW. Outcomes and predictors of skin [Na+] in dialysis
patients. Clin Kidney J. 2022 Jan 28;15(6):1129-1136. doi: 10.1093/ckj/sfac021. PMID:
35664280. This article is available under the terms of the Creative Commons Attribution License.

5.1 Introduction
Sodium-23 magnetic resonance imaging (23Na MRI) is an emerging imaging technique in clinical
nephrology.1 The potential of 23Na MRI lies in the ability to visualize and quantify [Na+] directly
at the tissue level – of special interest in CKD and dialysis population where sodium excretion is
impaired as a consequence of kidney failure. Methods to quantify skin [Na+] are attracting
increasing interest to study peripheral edema and water-independent sodium accumulation;2
however, clear evidence linking skin [Na+] with clinical outcomes is currently lacking. At present,
ECV overload is a well-described predictor of clinical outcomes in the kidney failure population
receiving dialysis.3,4 Skin water-independent sodium accumulation likely plays an additional
clinically significant role: this has been linked with increased left ventricular mass in non-dialysis
CKD patients, independently of ECV overload.5 Furthermore, skin [Na+] has been shown to be
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modifiable by interventions such as loop diuretics, SGLT2 inhibitors and ultrafiltration with HD.6–
8

Skin [Na+] may be an attractive and modifiable biomarker to assess volume status to be directly

addressed therapeutically.
In the present study, we explored the hypothesis that skin [Na+] is associated with mortality and
major adverse cardiovascular events (MACE) in a cohort of HD and PD patients who underwent
interdialytic

23

Na MRI of the leg. Furthermore, we aimed to define the determinants associated

with increased skin [Na+].
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5.2 Materials and Methods
Study design
This was an observational, exploratory study. Study participants underwent a visit consisting of a
research imaging session (1H and 23Na MRI of either the right or left leg), demographic and clinical
data collection and blood biochemistry. HD patients were scanned on the day following their last
HD treatment, whenever feasible. Outcomes were assessed retrospectively by clinical chart
review.
The study received approval from the Western University Human Research Ethics board and was
conducted in compliance with the Declaration of Helsinki and all applicable regulatory
requirements.

This

study

was

prospectively

registered

(ClinicalTrials.gov

Identifier:

NCT03004547).

Study participants
Study patients were recruited between March 2018 to March 2020 from the London Health
Sciences Centre (LHSC), London, ON, Canada. All study participants provided written informed
consent. Study participants were recruited from the prevalent LHSC outpatient dialysis population
and were on their established treatment modality (thrice-weekly HD or PD) for at least three
months before recruitment. Potential study candidates were excluded if pregnant, breastfeeding or
intending pregnancy, unable to provide consent or had contraindications to MRI.

Dialysate [Na+] prescription
Dialysate [Na+] was prescribed either according to dialysis unit protocol – within the LHSC
organization, one unit used 137 mmol/L and the other 140 mmol/L – or individualized following
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clinical indications (e.g. to match low serum [Na+] or improve intradialytic hemodynamic stability)
in selected patients. HD standard-of-care did not differ between units, except for dialysate [Na+]
prescription.

Magnetic Resonance Imaging and Image Analysis
All magnetic resonance images were acquired using a multinuclear 3.0 Tesla GE MRI scanner
(Discovery MR750, General Electric Healthcare, Milwaukee, WI, USA). To acquire

23

Na spin

density images, subjects were positioned in the magnet bore in the supine position, with the
thickest part of their right or left calf muscle at the center of a custom-made

23

Na birdcage

radiofrequency coil. Calibration vials with increasing saline concentrations were placed in the RF
coil over the subjects’ shins. A single-slice

23

Na MR image was obtained with a radial k-space

acquisition pulse sequence (Density-Adapted 2D Projection Reconstruction),9 with the following
parameters: slice-selective radiofrequency pulse; flip angle 90°; repetition time/echo time: 100/1.2
msec; number of signals averages: 100; slice thickness: 30 mm and isotropic field of
view/resolution: 18/0.3 cm2; total acquisition time: ~30 minutes. During the same imaging session,
additional axial 1H MR images were acquired using a standard (Spoiled Gradient-Recalled Echo)
pulse sequence to identify and delineate the relevant anatomical structures.
23

Na concentration maps were generated using custom software developed within MATLAB,

version 9.6.0 – R2019a (The MathWorks Inc., Natick, Massachusetts). A region of interest
encompassing the whole skin (Skin [Na+]) was manually segmented after superimposing 1H and
23

Na images, as detailed previously.10
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Laboratory Analysis
Blood samples collected from each participant were processed and analyzed in a central laboratory
(London Health Sciences Centre, London, Ontario, Canada) for routine clinical biomarkers. Due
to the high prevalence of diabetes mellitus in the study sample, serum sodium was corrected for
serum glucose concentration as according to Katz.11

Outcomes and Statistical Analysis
Statistical analysis was performed using GraphPad Prism version 9.0.0 (GraphPad Software, San
Diego, CA, USA; www.graphpad.com) and SPSS Version 27.0 (IBM Corp. Released 2020. IBM
SPSS Statistics for MacIntosh, Armonk, NY: IBM Corp). Normality was assessed both graphically
and with the Shapiro–Wilk test. Continuous variables were presented as mean (standard deviation,
SD) if normally distributed and median (minimum, interquartile range (IQR), maximum) if highly
skewed. Categorical variables were expressed as ratios or percentages. The study sample was
stratified into four groups according to skin [Na+] quartiles. Comparisons between two subgroups
were performed with the Mann-Whitney U test; differences between quartiles were computed
using one-way analysis of variance (ANOVA). The following outcomes were of interest for this
study: all-cause mortality and a composite of all-cause mortality and MACE, the latter defined as:
acute coronary syndrome, congestive heart failure, stroke, pulmonary embolism. Outcomes were
determined by clinical chart review and adjudicated by FRS and CWM. Participants who received
kidney transplantation were right censored at the transplant date. Survival or event-free survival
curves for each group were compared using the Kaplan-Meier function, and the log-rank test was
used to analyze survival trends, assuming an incremental risk with increasing skin [Na+] quartiles.
This analysis was performed for all-cause mortality and the composite endpoint of mortality and
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MACE. For both endpoints, univariate Cox proportional hazards regression was used to model the
hazard ratios associated with skin [Na+], either as a continuous or as a categorical variable;
multivariate models were created using the enter method to adjust skin [Na+] hazard ratios for
confounder variables commonly associated with mortality and MACE (age, sex, serum [Na+],
serum albumin), with the idea that skin [Na+] would be associated with clinical outcomes, even
after adjustment for basic demographics and traditional predictors of cardiovascular morbidity and
all-cause mortality (serum albumin and serum [Na+]).
Univariate linear regression was used to analyze the relationship between skin [Na+] and main
variables of interest (dialysate [Na+], corrected serum [Na+], serum albumin and age). Multiple
linear regression analysis with the enter method was used to model the variables associated with
skin [Na+]; the models were assembled to describe the dependence of skin [Na+] from variables
associated with volume overload (hypoalbuminemia, congestive heart failure), traditional
measures of sodium status (serum [Na+]), dialysis-based factors (dialysate [Na+]) and
demographics (age). Independent variables were selected according to the following criteria: (1)
previous published evidence (age, serum albumin, dialysate [Na+]),8,10,12 (2) pathophysiological
rationale (congestive heart failure, serum [Na+]), (3) statistically significant difference across the
skin [Na+] quartiles (serum albumin, dialysate [Na+], serum [Na+]).To avoid model overfitting, no
more than one predictor or confounder variable every ten cases was used in the models. Missing
data was handled by list-wise deletion. Unstandardized β coefficients, R-squared and adjusted Rsquared values for goodness-of-fit were reported. An α<0.05 was considered statistically
significant.
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5.3 Results
A total of 52 patients (42 HD and 10 PD) completed the study. Table 5.1 shows the main
characteristics of the study sample, as overall and after quartile stratification according to skin
[Na+].

Table 5.1: Demographics, anthropometrics, clinical information and medications of the overall study sample and after Skin
[Na+] quartile stratification.

Skin [Na+]
Q1
11

Skin [Na+]
Q2
13

Skin [Na+]
Q3
15

Skin [Na+]
Q4
13

p

63.9 ±
10.2
30/22

59.0 ± 9.8

64.2 ± 8.2

67.1 ± 7.8

7/4

64.4 ±
13.9
6/7

8/7

9/4

30.1 ± 6.4

29.6 ± 7.2

30.3 ± 5.4

30.1 ± 5.5

30.4 ± 8.1

0.2
88
0.6
38
0.9
91

42/10

11/0

11/2

11/4

9/4

22.0 (11.833.5)
250.0 (0.0750)

22.0 (19.029.5)
0.0 (0.0150.0)

23.0 (14.037.0)
250.0 (0.0400.0)

5.0 (4.07.0)

7.0 (5.08.0)

16.0 (4.024.0)
300.0
(100.0900.0)
7.0 (6.09.0)

0.8
59
0.2
19

6.0 (5.08.0)

21.0 (12.532.0)
400.0
(200.01000.0)
6.0 (4.08.5)

Hypertensive Nephrosclerosis (%)

15%

18%

31%

13%

0%

Diabetic Kidney Disease (%)

44%

27%

54%

27%

69%

Glomerular Disease (%)

10%

0%

0%

20%

15%

Other (%)

25%

55%

8%

33%

8%

Unknown (%)

6%

0%

8%

7%

8%

0.1
84
0.0
74
0.1
78
<0.
05
0.8
32

Hypertension (%)

79%

82%

77%

67%

92%

Coronary Artery Disease (%)

35%

18%

38%

33%

46%

Congestive Heart Failure (%)

27%

18%

23%

27%

38%

Variable
n
Age (years)
Sex (M/F)
BMI (kg/m2)
HD/PD
Dialysis Vintage (months)
(Median (IQR))
Residual Urine Output (ml/24h)
(Median (IQR))
CCI (Median (IQR))

Overall
52

0.2
84

CKD Etiology

Comorbidities
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0.4
18
0.5
37
0.7
04

Diabetes Mellitus (%)

60%

36%

69%

53%

77%

0.1
84

ACEi-ARB (%)

29%

27%

38%

7%

46%

Beta Blockers (%)

52%

45%

69%

33%

62%

Calcium Channel Blockers (%)

52%

45%

38%

53%

69%

Diuretic (%)

50%

36%

54%

53%

54%

0.1
07
0.2
31
0.4
4
0.7
92

22.5 (20.224.7)
1.30 ±
0.23
138.0
(137.0140.0)
2.1 ± 1.2

22.5 (20.123.2)
1.26 ±
0.28
137.0
(137.0137.0)
2.1 ± 1.0

23.9 (22.625.2)
1.34 ±
0.23
138.0
(137.0140.0)
2.1 ± 1.0

21.0 (20.333.3)
1.32 ± 0.19
140.0
(137.5140.0)
1.8 ± 1.3

22.8 (18.523.6)
1.26 ±
0.26
140.0
(140.0140.0)
2.3 ± 1.5

UFR (ml/kg/h)

7.6 ± 3.7

8.3 ± 4.7

8.2 ± 3.3

7.1 ± 3.5

6.7 ± 3.5

PreHD SBP (mmHg)

142.5 ±
22.8
62.8 ±
15.3

137.3 ±
25.7
68.0 ±
19.4

153.5 ±
21.5
59.5 ±
15.1

142.1 ±
14.0
67.0 ± 8.4

135.9 ±
27.4
55.1 ±
14.6

30.8 ±
11.3

17.4 ± 3.2

25.7 ± 2.5

31.7 ± 1.7

46.1 ± 8.6

<0.
001

136.2 ±
5.1
4.6 ± 0.9

136.3 ±
2.1
4.2 ± 0.7

139.2 ± 2.1

Serum [K+] (mmol/L)

137.9 ±
3.3
4.4 ± 0.7

4.4 ± 0.7

139.3 ±
2.6
4.4 ± 0.6

Serum [HCO3-] (mmol/L)

24.9 ± 4.0

22.9 ± 3.3

26.5 ± 3.9

26.4 ± 3.2

23.3 ± 4.6

Serum Creatinine (umol/L)
Serum Urea (mmol/L)

630.5 ±
231.8
19.1 ± 6.8

735.7 ±
271.2
24.1 ± 6.3

614.0 ±
192.3
17.0 ± 4.6

603.4 ±
240.9
17.0 ± 6.8

589.3 ±
221.8
19.2 ± 7.2

Serum Glucose (mmol/L)

8.5 ± 3.9

8.0 ± 3.5

7.7 ± 2.3

9.0 ± 5.4

9.0 ± 3.5

Serum Albumin (g/L)

39.9 ± 3.9

42.8 ± 3.8

41.1 ± 2.2

39.1 ± 3.6

37.2 ± 3.9

112.4 ±
14.2

116.8 ±
16.8

113.2 ±
13.9

113.5 ±
13.2

106.5 ±
13.1

<0.
05
0.5
9
<0.
05
0.4
09
<0.
05
0.7
59
<0.
01
0.3
39

Medications

Hemodialysis Information (n=42)
Time Elapsed from Last HD to
MRI (hours) (Median (IQR))
spKt/V
Dialysate [Na+] (mmol/L) (Median
(IQR))
IDWG (%body weight)

PreHD DBP (mmHg)

23

0.5
23
0.8
56
<0.
001
0.8
8
0.7
13
0.2
79
0.1
8

Na MRI

Skin [Na+] (mmol/L)

Laboratory Analyses
Corrected Serum [Na+] (mmol/L)

Hemoglobin (g/L)
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Data are expressed as mean ± SD unless otherwise noted. ACEi: angiotensin converting enzyme
inhibitors; ADKPD: autosomal dominant polycystic kidney disease; APD: automated peritoneal
dialysis; ARB: angiotensin II receptor blocker; BMI: body mass index; CAPD: continuous
ambulatory peritoneal dialysis; CCI: Charlson comorbidity index; CKD: chronic kidney disease;
DBP: diastolic BP; HD: hemodialysis; IDWG: interdialytic weight gain; IQR: interquartile range;
PD: peritoneal dialysis; preHD: pre-dialysis; SBP: systolic BP; spKt/V: single-pool Kt/V; UFR:
ultrafiltration rate.

Study participants tended to be older as skin [Na+] quartiles increased. Participants in Q4 tended
to have a shorter dialysis vintage, larger comorbidity burden and more anti-hypertensive
medications compared with Q1-Q3. Participants in Q3 and Q4 also tended to higher dialysate [Na+],
corrected serum [Na+] and lower serum albumin compared with Q1 and Q2. Eight out of 42 HD
patients were receiving an individualized dialysate [Na+] prescription (median, range: 138
mmol/L, 135-145); 17 patients were receiving a dialysate [Na+] prescription of 137 mmol/L; 17
patients were receiving a dialysate [Na+] prescription of 140 mmol/L. Dialysate [Na+] distribution
according to skin [Na+] quartiles is shown in Figure 5.1.
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Figure 5.1: Dialysate [Na+] prescription in HD patients, according to skin [Na +] quartiles. Data is presented as median (bars)
and individual values.

The distribution of PD patients was skewed towards the upper skin [Na+] quartiles. This
determined a trend towards a greater residual urine output in Q3-Q4, as PD patients had a
significantly greater residual urine output compared with HD patients (median (IQR):1125 (6001575) vs 200 (0-400) mL/24h, Mann-Whitney U-test p<0.001). HD patients were scanned after a
median 22.5 (IQR: 20.2-24.8) hours after their last HD session. In a minority of participants (6/42
cases), MRI was performed during the long interdialytic interval (between the 3rd and before the
1st HD session of the week), after (median (IQR)) 45.9 (44.5-47.4) hours from the previous HD
session. In the remaining cases (36/42) MRI was performed mid-week during a short HD interval,
between either the 1st and 2nd or 2nd and 3rd HD session, after (median (IQR)) 21.8 (19.8-23.3)
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hours from the previous HD session. No significant differences in time were observed among skin
[Na+] quartiles.

Linear Regression Models
Univariate linear regression yielded the following results (Table 5.2): Dialysate [Na+] was
significantly and positively associated with skin [Na+] (F(1,40)= 26.79, R2=0.40, unstandardized
β = 3.79, p<0.001)); serum albumin was significantly and negatively associated with skin [Na+]
(F(1,50)= 12.62, R2=0.20, unstandardized β = -1.30, p<0.001)); corrected serum [Na+] was
significantly and positively associated with skin [Na+] (F(1,50)= 10.214, R2=0.17, unstandardized
β = 1.39, p<0.01)). The relationship between skin [Na+] and age did not reach statistical
significance (F(1,50)= 3.443, R2=0.06, unstandardized β = 0.28, p=0.07).
The results of the multiple linear regression analysis are summarized in Table 5.2. Using the enter
method, Model 1 explained a significant amount of the variance in skin [Na+] in HD patients
(F(4,37)= 17.82, p<0.001, R2=0.66, R2adj=0.62). In particular, the following predictors were
statistically significant: dialysate [Na+] (unstandardized β = 3.33, p<0.001), Serum albumin
(unstandardized β = -1.18, p<0.001), comorbid congestive heart failure (unstandardized β = 7.07,
p<0.01).
Model 2 included variables from both HD and PD patients, and was significant as well (F(3,48)=
7.35, p<0.001, R2=0.32, R2adj=0.27). Compared with Model 1, after the removal of dialysate [Na+],
corrected serum [Na+], serum albumin (unstandardized β = -1.11, p<0.01) and comorbid
congestive heart failure (unstandardized β = 7.76, p<0.05) were statistically significant explanatory
variables of skin [Na+].
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Table 5.2: Multiple Linear Regression models to explain Skin [Na+].

Model 1: Dependent Variable: Skin [Na+] (HD)
F(4,37)= 17.82, R2=0.66, R2Adj=0.62, p<0.001
Independent Variable

Unstandardized β

p

-453.62

<0.001

Dialysate [Na ]

3.33

<0.001

Serum Albumin

-1.18

<0.001

Congestive Heart Failure

7.07

<0.01

0.50

0.18

Unstandardized β

p

-124.83

<0.05

Corrected Serum [Na ]

1.29

<0.01

Serum Albumin

-0.89

<0.05

Congestive Heart Failure

9.33

<0.01

Age

0.17

0.17

(Intercept)
+

Corrected Serum [Na+]
+

Model 2: Dependent Variable: Skin [Na ] (HD & PD)
F(4,47)= 9.573, R2=0.45, R2Adj=0.40, p<0.001
Independent Variable
(Intercept)
+

Outcomes
Follow-up and survival times, censoring, clinical events are summarized in Table 5.3. Of note,
median follow-up time for the overall sample was 529 days (IQR: 353-602). 15 deaths and seven
MACE were observed during the follow-up period. 11 participants were right-censored after a
median of 215 days (IQR: 99-289) due to kidney transplantation.
For the endpoint of all-cause mortality, survival distributions for the skin [Na+] quartiles
significantly differed (log-rank χ2(1) = 3.926, p for trend <0.05) (Figure 5.2A), as well as eventfree survival distributions for the composite endpoint of death and MACE (log-rank χ2(1) = 5.685,
p for trend <0.05) (Figure 5.2B).
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Figure 5.2: Kaplan-Meier curves for overall survival (A) and event-free survival as a composite of all-cause mortality and major
adverse cardiovascular events (B), after skin [Na+] quartile stratification.

Mean survival and event-free survival times for each skin [Na+] quartile group are summarized
in Table 5.3.

Table 5.3: Summary of follow-up times, survival and clinical events, in the overall study sample and after Skin [Na+] quartile
stratification.

Follow-up time (median (IQR))

Mean Est. Survival (mean (95% CI))

Mean Est. Composite Event-free
Survival (mean (95% CI))
Clinical Events
Kidney Transplant (n)
MACE (n)
Death (n)

Overall

Q1

Q2

Q3

Q4

529
(353602)
847
(716975)
741
(602880)

546 (515592)

505 (292533)

588 (421685)

1020 (9011140)

873 (5871159)

875 (6631087)

994 (8271160)

754 (4681041)

667 (473861)

544
(133577)
657
(420895)
537
(301774)

3
1
1

2
1
3

3
2
4

11
7
15

3
3
7

CI: 95% confidence interval; IQR: interquartile range; MACE: major adverse cardiovascular
events
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According to univariate Cox proportional hazards regression (Table 5.4), skin [Na+] was
significantly associated with all-cause mortality as a continuous variable (HR per 10 mmol/L skin
[Na+] increments: 1.832, 95% CI: 1.234-2.720) and with composite events, both as a continuous
variable and as a categorical variable (HR per 10 mmol/L skin [Na+] increments: 1.722, 95% CI:
1.226-2.418; HR per skin [Na+] quartile increment: 1.767, 95% CI: 1.089-2.866). In multivariate
models, skin [Na+] was associated with all-cause mortality after adjusting for age, sex, corrected
serum [Na+] and serum albumin (HR per 10 mmol/L skin [Na+] increments: 4.013, 95% CI: 1.9888.101, p<0.001; HR per skin [Na+] quartile increment: 3.180, 95% CI: 1.314-7.700, p<0.05).
Similarly, skin [Na+] was also associated with composite all-cause mortality and MACE (HR per
10 mmol/L skin [Na+] increments: 2.332, 95% CI: 1.378-3.945, p<0.01; HR per skin [Na+] quartile
increment: 2.038, 95% CI: 1.058-3.925, p<0.05)

Table 5.4: Cox proportional hazard regression to model the association between Skin [Na +] and clinical outcomes, before and
after confounder adjustment.

Endpoint: All-cause mortality

Univariate

Model 1

Model 2

Variables

HR (95% CI)

p

HR (95% CI)

p

HR (95% CI)

p

Skin [Na+] (per 10 mmol/L)

1.832 (1.2342.720)
1.709 (0.9892.954)
1.014 (0.9651.065)
0.225 (0.0630.805)
0.975 (0.8541.113)
0.971 (0.8381.124)

<0.0
1
0.05
5
0.58
4
<0.0
5
0.70
8
0.69
2

4.013 (1.9888.101)
-

<0.0
01
-

-

-

0.996 (0.9341.063)
0.156 (0.0390.630)
0.711 (0.5590.904)
1.031 (0.8831.202)

0.912

3.180 (1.3147.700)
1.002 (0.9411.067)
0.217 (0.0590.796)
0.786 (0.6210.995)
1.099 (0.9191.313)

<0.0
5
0.94
9
<0.0
5
<0.0
5
0.30
2

Skin [Na+] (per quartile)
Age
Sex (female vs male)
Corrected Serum [Na+]
Serum Albumin

Endpoint: All-cause mortality +
MACE
Variables
+

Skin [Na ] (per 10 mmol/L)

Univariate

<0.0
1
<0.0
1
0.702

Model 1

Model 2

HR (95% CI)

p

HR (95% CI)

p

HR (95% CI)

p

1.722 (1.2262.418)

<0.0
1

2.332 (1.3783.945)

<0.0
1

-

-

143

Skin [Na+] (per quartile)
Age
Sex (female vs male)
Corrected Serum [Na+]
Serum Albumin

1.767 (1.0892.866)
1.023 (0.9791.068)
0.315 (0.1120.885)
1.046 (0.9121.201)
0.926 (0.8081.062)

<0.0
5
0.30
9
<0.0
5
0.51
8
0.27
3

-

-

0.996 (0.9461.050)
0.291 (0.0990.859)
0.849 (0.6951.036)
0.979 (0.8461.133)

0.894
<0.0
5
0.107
0.775

2.038 (1.0583.925)
1.001 (0.9501.055)
0.314 (0.1100.898)
0.921 (0.7591.117)
1.012 (0.8621.189)

<0.0
5
0.95
9
<0.0
5
0.40
4
0.88
0

[Na+]: sodium concentration; 95% CI: 95% confidence interval; HR: hazard ratio; MACE: major
adverse cardiovascular events
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5.4 Discussion
We report for the first time that increasing skin [Na+] is associated with increased mortality and
MACE. Dialysate [Na+], corrected serum [Na+], serum albumin and congestive heart failure were
significant clinical predictors of skin [Na+] in dialysis patients.
The main finding of this study is that skin sodium accumulation is associated with worse clinical
outcomes, potentially as the result of a combination of processes depositing sodium within tissues.
The simplest explanation for this finding is that noninvasive tissue sodium detection by 23Na MRI
reflects the degree of tissue congestion/edema. From a mechanistic perspective, this explanation
is supported by previous experimental evidence. A recent comprehensive study in rats and humans
showed that tissue [Na+] in rats and skin [Na+] in humans is paralleled by water content (“isotonic”
sodium accumulation) as a direct function of ECV expansion, and inversely with intracellular
volume and potassium concentration.13 Similar data have been shown in a mathematical model
relating total tissue [Na+] with ECV.2 However, these observations are derived from
animals/subjects without significant CKD and impaired ability to excrete sodium.
Noninvasive, human-based

23

Na MRI studies confirmed the close relationship between sodium

and water at the tissue level: both diuretics6,7 and ultrafiltration with HD8 have been associated
with tissue [Na+] reduction. At the epidemiological level, clinical outcomes are correlated with
surrogate measures of ECV expansion, such as fluid overload detected with bioimpedance
spectroscopy3,4 and lung ultrasound.14
In the present study, the hypothesis of the relationship between sodium and water at the skin level
is supported by the significant explanatory role of serum albumin and comorbid congestive heart
failure on skin [Na+]. Indeed, these two factors are associated with positive net capillary filtration,
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according to the Starling equation: increased plasma hydrostatic pressure (congestive heart failure)
and reduced plasma oncotic pressure (hypoalbuminemia).
However, the additional, explanatory role of dialysate [Na+] suggests that sodium accumulation
may also occur in excess of water, as shown by several preclinical studies.15 Increased sodium
intake in rats was associated with increased skin [Na+] and followed by lymph capillary expansion,
via macrophage-mediated, tonicity-sensitive VEGF-C secretion; dysfunction in this system was
associated with increased skin [Na+] and the downregulation of the endothelial nitric oxide
synthase.16 In humans, we recently showed that chronic HD patients receiving a dialysate [Na+] of
140 mmol/L had larger skin [Na+] compared with patients receiving a dialysate [Na+] of 137
mmol/L, based on different unit prescription protocols.17 This evidence suggests that skin [Na+]
accumulation resulting from intradialytic positive diffusive sodium balance may be an additional
factor leading to worse clinical outcomes. Although we cannot discern the pathophysiological
mechanisms linking water-free skin [Na+] with increased mortality and cardiovascular events,
recent studies have suggested that skin [Na+] may exert “toxic” effects on the cardiovascular
system, such as BP and left ventricular mass, independently of ECV.5,16
Hypoalbuminemia is a well-known predictor for all-cause mortality in dialysis patients; according
to our results, we speculate that the relationship between low serum albumin and clinical outcomes
is mediated by overt or subclinical tissue congestion. Indeed, we showed a continuous negative
relationship between serum albumin and skin [Na+], so that even small reductions in serum
albumin were associated with larger skin [Na+] – likely as the result of reduced plasma oncotic
pressure.18 Other potential mechanisms linking hypoalbuminemia with clinical outcomes in
chronic dialysis patients may be related with reduced albumin synthesis due to inflammation and
reduced protein-calorie intake,19 and impaired endothelial barrier with resulting transcapillary
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escape rate of albumin and intercompartmental albumin redistribution.20 Differently than previous
studies,8,12 we did not find a significant correlation between age and skin [Na+], as well as clinical
outcomes. This is likely the result of several combined factors: (a) small study sample, (b) limited
age range in the study population, (c) the greater influence of other clinical and sodium-related
variables, suggesting the primary relevance of volume and sodium balance in the dialysis
population.
Several limitations must be considered when interpreting the present study findings. This is an
observational, exploratory study and other potentially relevant confounders associated with
outcomes have not been included in the statistical models due to the small sample size and related
lack of statistical power. Eight out of 42 HD patients were receiving individualized dialysate [Na+]
prescription: although dialysate [Na+] was significantly associated with skin [Na+], it is possible
the clinical factors underlying dialysate [Na+] individualization may have influenced outcomes.
We assumed that an interdialytic, cross-sectional evaluation of skin [Na+] would be associated
with clinical outcomes, assuming no longitudinal changes in skin [Na+] during the follow-up
period. Evaluation of all-cause mortality and MACE was limited by the small number of patients
included in the study, right censoring by kidney transplantation and short follow-up times.
Due to the small and unequal sample size it was not possible to differentiate the impact of different
dialytic techniques (HD vs PD) on skin [Na+] and clinical outcomes. Inherently different volume
and sodium removal strategies associated with these techniques, however, might have a separate
impact on skin [Na+] and clinical outcomes. Additional studies are required to confirm this
hypothesis.
In conclusion, higher skin [Na+] (as quantified with 23Na MRI) was associated with worse clinical
outcomes in dialysis patients. Although potential unaccounted confounding effects may be at play,
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these findings suggest sodium balance may play an important role in the care of dialysis patients,
from both a traditional view (with expansion of ECV) and as a function of our evolving
understanding of water-free sodium accumulation within tissues. Future studies investigating the
role of skin [Na+] as a quantitative imaging biomarker for risk stratification, therapy optimization
and as a potential direct therapeutic target are necessary.
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Chapter 6
6.1 Overview and Research Questions
ECV expansion in CKD has been known to be associated with adverse cardiovascular effects such
as hypertension and left ventricular hypertrophy, as well as adverse clinical outcomes such as
myocardial infarction, heart failure and death, since the earlier days of renal replacement therapy.1–
4

According to compartment physiology, ECV expansion is mostly made of water, sodium and its

counter anions chloride and bicarbonate.5–7 Recent studies have also identified the human body’s
capability to store sodium without commensurate water retention, mainly at the skin dermis level,
where sodium’s main counter anion would be negatively-charged sulfated proteoglycans.8,9 These
studies suggests that the toxic effects of sodium may be beyond ECV expansion.

23

Na MRI has

the ability to visualize tissue sodium directly, and is currently the most accurate way to estimate
total body sodium in vivo.
Although ECV control is a fundamental target of renal replacement therapy,10 achieving optimal
balance with current dialysis practices is challenging – removal of large volumes of water and
sodium within a standard four-hour HD treatment is frequently burdened by cardiovascular
complications.11,12 This required HD clinical practice to change by increasing dialysate [Na+],
improving intradialytic hemodynamic stability, which in turn resulted in increased total body
sodium and cardiovascular adverse effects.13
In this setting, the goal of this work was to exploit 23Na MRI to investigate the relationship between
tissue [Na+] and CKD, with a particular focus on patients receiving chronic renal replacement
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therapy, with particular regards to the associated predictors of tissue [Na+] and its effects on
cardiovascular surrogates (left ventricular mass) and clinical outcomes.

The following research questions were addressed by this work:
● Chapter 2. How does tissue [Na+] relate to CKD, HD and PD in adult individuals? Are
there any relevant clinical predictors relating to tissue [Na+]?
● Chapter 3. How does tissue [Na+] relate to kidney disorders in childhood? What are its
clinical predictors?
● Chapter 4. How does tissue [Na+] relate to cardiac structural parameters and geometrical
abnormalities in HD patients?
● Chapter 5. How does tissue [Na+], particularly at the skin level, relate to clinical outcomes
in patients receiving dialysis? What are its main clinical predictors?

6.2 Summary and Conclusions
The findings of this thesis work may be summarized as follows:
● Chapter 2: Tissue [Na+] in the skin and the soleus muscle were higher in HD and PD
patients compared to controls. Serum albumin showed a strong, negative correlation with
soleus [Na+] in HD patients (r=-0.81, p<0.01). eGFR showed a negative correlation with
tissue [Na+] (Soleus: r=-0.58, p<0.01, Tibia: r=-0.53, p=0.01) in merged Control-CKD
patients.
● Chapter 3: No significant differences were found between healthy children/adolescents
and CKD patients. In comparison, healthy adults had significantly higher tissue [Na+]
compared with pediatric groups, suggesting age is a strong predictor of tissue [Na+]. Four
CKD patients with glomerular disease and one kidney transplant recipient due to atypical
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hemolytic-uremic syndrome had elevated whole-leg [Na+] Z-scores. Reduced whole-leg
[Na+] Z-scores were found in two patients with tubular disorders (Fanconi syndrome,
proximal-distal renal tubular acidosis). All tissue [Na+] measures had a significant positive
association with proteinuria and negative association with serum albumin concentration
● Chapter 4: Both skin [Na+] and whole-leg [Na+] were positively associated with greater
LVMI (Skin [Na+]: r=0.425, p<0.05; whole-leg [Na+]: r=0.480, p<0.05) and LVEDV/BSA
(skin [Na+]: r=0.494, p<0.01; whole-leg [Na+]: r= 0.447, p<0.05). Concentric hypertrophy
(normal geometry vs concentric hypertrophy: 19.2±3.4 mmol/L vs 28.1±6.9 mmol/L,
p<0.05) and eccentric hypertrophy (normal geometry vs eccentric hypertrophy: 19.2±3.4
mmol/L vs 36.3±12.5 mmol/L, p<0.01) were associated with higher skin [Na+] compared
to normal geometry.
● Chapter 5: Increasing skin [Na+] quartiles were associated with significantly shorter
overall and major cardiovascular adverse event-free survival (log-rank χ2(1) = 3.926, logrank χ2(1) = 5.685, p for trend <0.05 in both instances). Skin [Na+] was associated with allcause mortality (HR 4.013, 95% CI: 1.988-8.101, p<0.001) and composite events (HR
2.332, 95% CI: 1.378-3.945, p<0.01), independently of age, sex, serum [Na+] and serum
albumin. In multiple regression models, dialysate [Na+], serum albumin and congestive
heart failure were significant predictors of skin [Na+] in HD patients (R2adj=0.62).

In conclusion, this work provided evidence that (1) eGFR and CKD per se are marginally
associated with increased tissue [Na+], whereas some specific etiologies are associated with either
accumulation or depletion; (2) end-stage CKD requiring renal replacement therapy is associated
with tissue sodium accumulation; (3) the main predictors of tissue [Na+] (age, serum albumin,
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dialysate [Na+] and congestive heart failure) suggest a multitude of mechanisms of tissue sodium
accumulation, including tissue composition, hydrostatic and oncotic forces and intradialytic
sodium intake; (4) tissue [Na+] is associated with left ventricular hypertrophy and dilatation in HD
patients; (5) skin [Na+] is associated with major cardiovascular adverse events and mortality in
patients receiving renal replacement therapy.

6.3 Limitations
As the main limitations associated with the individual studies were already covered in Chapters 2
to 5, only the general limitations associated with the study designs and methodology will be
addressed below.

Generally, the studies of this work are characterized by an exploratory design and a small sample
size. This may translate into false negative results due to the studies being underpowered. When
possible, an a priori sample size calculation was performed (Chapter 4). The most evident
example are: the relationship between eGFR and tissue [Na+] in Chapter 2, and in Chapter 3,
where each individual pediatric CKD etiology was modestly represented.

The studies were cross-sectional or observational in nature, and lack an interventional component.
This was mainly due to the difficulties associated with designing clinical trials in the HD setting,
requiring the recruitment and retention of a large number of participants and with complex
treatment schedules.14,15
The 23Na MRI technique we employed comes with several limitations, that invite some degree of
caution when interpreting the results from this study. First, image acquisition comes with a single
30 mm-slice and a 3x3 mm2 planar resolution. This signifies that the
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23

Na signal from each

individual voxel will be the result of the average of sodium ions from all tissues contained within
it, as a result of the partial volume effect. Indeed, a weak

23

Na signal is therefore the result of

different voxel compositions: interstitial tissue (high in sodium), cellular tissue and fat tissue (both
low in sodium content). At the muscle level, a weak
whereas a strong

23

23

Na signal may reflect healthy muscle,

Na signal may reflect muscle mass loss and interstitial tissue replacement

(cachexia). Second, a recent study posited the possibility that UTE pulse sequences, such as the
one we employed in this work, are unable to measure significant signal from the sodium bound to
skin proteoglycans.16 This would signify that the signal we detect does not include water-free
sodium, but only sodium dissolved in water, mainly in the ECV. This observation, however,
requires further confirmation and is, to our knowledge, limited to this report. Third, due to its
limited availability, elevated cost and technical expertise, as well as prolonged scan time, the
diffusion of

23

Na MRI is going to be challenging, especially in the renal replacement therapy

setting, where sodium measurements may be required to be repeated several times of the course of
a year. This limits the use of this technique to the clinical trial setting or to selected clinical cases
in third-level university hospital settings, in which the use of 23Na MRI may be deemed essential
to make complex management and therapeutic decisions. Nonetheless, the potential clinical
significance of tissue [Na+] may encourage a wider implementation of

23

Na MR technology to

commercial MRI scanners and diffusion of this technology in daily clinical practice in the future.

6.4 Significance of the Results
Despite the initial focus on ECV balance, sodium restriction and BP control of the earlier renal
replacement therapy days,1,13,17 more recent HD practices have since focused on highly efficient
blood depuration, based on urea clearance-derived measures (namely urea reduction ratio and
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Kt/V), at the expense of less efficient fluid removal and higher dialysate [Na+].18 This work
provides evidence in support of the recent “Volume First” in dialysis policies proposed in the
United States19 and Canada.20 Briefly, these policies support strict ECV and sodium balance as a
vital goal for optimal dialysis, by exploiting HD treatment times no shorter than 4 hours per
session, use of dialysate [Na+] < 139 mmol/L and dietary counseling to limit salt intake.
This is fundamental as cardiovascular disease is the first cause of death in CKD, with CKD patients
displaying both “traditional” and “atypical” risk factors for cardiovascular disease.21,22
A significant body of research by Christopher McIntyre et al was dedicated to demonstrating how
hemodynamic instability during HD is responsible for the high cardiovascular morbidity and
mortality observed in the HD population.23–27 At the center of this idea, is that shortening HD
treatment times, both a necessity motivated by the high demand of renal replacement therapy in
developed countries and an opportunity made possible by the high depurative efficiency of modern
HD, is one of the main factors associated with the “unphysiology” of HD,28 concentrating a
normally continuous renal function in the short space of four hours three times per week. Indeed,
the cardiovascular system is often unable to tolerate large volumes of ECV removal without
developing recurrent ischemia-reperfusion injury during short HD treatments.
The other side of intradialytic hemodynamic instability is ECV expansion, or tissue sodium
accumulation. While the notion that ECV expansion is highly prevalent in CKD – especially if
requiring renal replacement therapy – is not new,29 this work points at tissue sodium accumulation
as the main target for future research and treatment strategies.
Other research groups have shown that CKD, HD and PD are associated with increased tissue
[Na+];30,31 in Chapter 2, we confirm these findings relative to HD and PD patients. To this body
of research, we add preliminary observations on pediatric CKD (Chapter 3), where we suggest
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that specific causes of kidney disease may lead to tissue sodium depletion (tubular disorders) or
tissue sodium accumulation (nephrotic syndrome). The significance of this observation is
uncertain, as we were unable to establish the clinical consequences of these findings, which require
further confirmation.
A German group has shown a linear relationship between skin [Na+] and left ventricular mass
(using cardiac MRI) in patients with CKD.32 Similarly, we have shown that tissue [Na+] is
positively associated with left ventricular mass and dilatation in CKD patients requiring HD
(Chapter 4). To our knowledge, however, this work is the first to show a direct relationship
between skin sodium accumulation with adverse clinical outcomes (Chapter 5). This observation
requires further and independent confirmation and poses the fundamental question of whether
tissue [Na+] reduction would translate into more favorable clinical outcomes.

6.5 Future Steps
This work set the basis for new promising lines of research that will be delineated below.
Hypothesizing a more extensive application of 23Na MRI in the clinical field, being able to define
what [Na+] values can be considered normal for each tissue becomes essential. This requires
scanning healthy individuals at a population scale, likely in the order of several thousands. As sex
and age have been shown to be significant predictors of tissue [Na+], normal values would be
defined according to sex and age for each tissue, in a manner similar to dual-energy x-ray
absorptiometry for the definition of osteoporosis or cardiac MRI for the definition of left
ventricular hypertrophy. This will allow to compute the Z-scores of the subject of interest against
the standard sex- and age-specific healthy tissue [Na+] value. Subsequently, a wider, population
scale application of 23Na MRI in specific patient groups (e.g. CKD not requiring dialysis, stratified
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by eGFR stage) will allow to define clearly whether significant deviations from normality have an
outcome significance, and establish useful surrogate outcomes for future tissue [Na+]-directed
interventional clinical trials.
As mentioned in the conclusion to the previous paragraph, interventions are necessary to test the
effect of tissue sodium reduction on clinical outcomes. In CKD patients receiving HD, the impact
of more frequent and/or prolonged HD schedules, addressing the “unphysiology” of HD by
allowing for more lenient ultrafiltration rates and lower dialysate [Na+] (thus achieving diffusive
sodium removal rather than accumulation), requires further testing. Indeed, frequent and prolonged
HD schedules have already been shown to be associated with a lesser degree of cardiac ischemiareperfusion injury,33 lower left ventricular mass,34 and a survival similar to the general population.3
In this setting, tissue sodium reduction may be more easily achievable due to better intradialytic
hemodynamic stability, and may be the main mechanism leading to improved left ventricular mass
and better survival.
Improved sodium removal strategies have also been recently designed in the setting of PD, with
specifically designed sodium-free hypertonic solutions (either containing 10% dextrose solution
or 30% icodextrin/10% dextrose solution), either in the setting of hybrid dialysis (i.e. using both
HD and PD sequentially to improve ECV management) or continuous ambulatory PD. Two
clinical trials are currently ongoing from our group (ClinicalTrials.gov Identifiers: NCT04603014
and NCT05185999).
In paragraph 6.3, we mentioned the inability of UTE pulse sequences for 23Na MRI to detect the
signal of sodium bound to proteoglycans, as it occurs at the dermal skin level.16 The potential for
triple quantum filtering 23Na MRI to detect these deposits opens up to a very interesting line of
research, allowing – from a physiological standpoint – to visually identify and quantify water-free
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tissue sodium deposits in vivo. Moving to the clinical setting, investigating the variability of dermal
skin sodium deposits between disease groups, the conditions associated with them, their clinical
significance and potential for clearance through specific treatment strategies would follow,
similarly to the structure of the present work.
The potential of 23Na MRI in CKD includes its application to other organs, especially the kidneys.
Here, the ratio between the sodium signal in the cortex and the medulla (sodium corticomedullary
ratio) has been associated with the kidneys’ capacity to concentrate the urine35

Figure 6.1: Anatomic 1H (A) and 23Na (B) MRI scans in a healthy volunteer and (C) corresponding overlaid 1H and 23Na images
for region of interest analysis.

Image reproduced with permission35

and may be employed, in perspective, as a sensitive biomarker of kidney injury in the critical care
setting, differentiating organic and irreversible tubular damage (acute tubular necrosis) from
functional and reversible forms of kidney failure (prerenal azotemia), or allowing the
quantification of residual kidney function in the CKD and dialysis settings.
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European Renal Association – European Dialysis and Transplantation Association (ERAEDTA), Virtual Congress 2020.

•

“Noninvasive assessment of pulmonary hypertension using quantitative imaging in
hemodialysis patients”. Salerno FR, Lindenmaier T, Matheson A, Eddy RL, McIntosh M,
Dorie J, Parraga G, McIntyre CW. [e-poster]. European Renal Association – European
Dialysis and Transplantation Association (ERA-EDTA), Virtual Congress 2020.

•

“Is Tissue Sodium Storage Driving Systemic Inflammation in Chronic Kidney Disease? A
Sodium Magnetic Resonance Imaging Study”. Akbari A, Hur L, Penny J, Qirjazi E,
Salerno FR, McIntyre CW. American Society of Nephrology Conference 2019,
Washington, DC, US.

•

“A Novel Magnetic Resonance Imaging Biomarker of Tibial Bone Quality in Chronic
Kidney Disease”. Salerno FR, Akbari A, Hur LY, McIntyre CW. American Society of
Nephrology Conference 2019, Washington, DC, US.

•

“Lung Ventilation Abnormalities in Chronic Hemodialysis Patients with Hyperpolarized
129
Xe Gas Magnetic Resonance Imaging”. Salerno FR, Eddy RL, Matheson AM, Parraga
G, McIntyre CW. American Society of Nephrology Conference 2019, Washington, DC,
US.

•

“Muscle Quality Assessment by Texture Analysis of 1H-Magnetic Resonance Images in
Chronic Kidney Disease Patients”. Hur LY, Salerno FR, Akbari A, McIntyre CW.
American Society of Nephrology Conference 2019, Washington, DC, US.
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•

February 15th-17th 2019: “Varying Intensity of Remote Ischemic Preconditioning to
Prevent Hemodialysis-Induced Cardiac Injury: a Randomized Controlled Trial”. Salerno
FR, Crowley L, Tamasi T, Penny JD, McIntyre CW. The 1st International University of
Florida Nephrocardiology Conference 2019, Orlando, FL, US.

•

October 25th-28th 2018: “Dose-Effect Response of Remote Ischemic Preconditioning for
the Prevention of Hemodialysis-Induced Myocardial Stunning: Preliminary Results of a
Randomized Controlled Trial”. Salerno FR, Crowley L, Penny JD, McIntyre CW.
American Society of Nephrology Conference 2018, San Diego, CA, US.

•

March 13th-15th 2015. “Alpha-galactosidase activity, high-sensitivity troponin T and
myocardial fibrosis in Fabry disease: a case series”. Salerno FR, Pieruzzi F, Di Gennaro
F, Binaggia A, Di Giacomo A, Torti G, Stella A. “PhD Fabry Research Initiative”, 14th
European Round Table on Fabry disease, Paris, France.

•

November 21st-22nd 2014: "Association between Anderson-Fabry disease clinical severity
and high-sensitivity troponin-T levels”. Salerno F, Pieruzzi F, Binaggia A, Di Giacomo
A, Torti G, Parini R, Rigoldi M, Stella A. “European Symposium on Lysosomal Storage
Disorders”, London, UK.

•

October 3rd-5th 2013: “[Effect of blood pressure on left ventricular mass, diastolic function
and cardiac geometry in children]”. Salerno F, Pieruzzi F, Antolini L, Giussani M,
Brambilla P, Galbiati S, Frizziero D, Mastriani S, Stella A, Valsecchi MG, Genovesi S.
30th congress of the Italian Society of Arterial Hypertension (SIIA), Rome, Italy.

Oral Presentations
“Associations of muscle sodium deposition with sodium-23 MRI in hemodialysis patients”.
Salerno FR, Akbari A, Lemoine S, Scholl T, McIntyre CW. European Renal Association –
European Dialysis and Transplantation Association (ERA-EDTA), Virtual Congress 2020, June
6th-9th 2020.
“Varying Intensity of Remote Ischemic Preconditioning to Prevent Hemodialysis-Induced Cardiac
Injury: a Randomized Controlled Trial”. Salerno FR, Crowley L, Tamasi T, Penny JD, McIntyre
CW. “The 1st International University of Florida Nephrocardiology Conference 2019”, Orlando,
FL, US. February 15th-17th 2019.
“Alpha-galactosidase activity, high-sensitivity troponin T and myocardial fibrosis in Fabry
disease: a case series”. Salerno FR, Pieruzzi F, Di Gennaro F, Binaggia A, Di Giacomo A, Torti
G, Stella A. “PhD Fabry Research Initiative”, 14th European Round Table on Fabry disease, Paris,
March 13th-15th 2015.
"Association between Anderson-Fabry disease clinical severity and high-sensitivity troponin-T
levels”. Salerno F, Pieruzzi F, Binaggia A, Di Giacomo A, Torti G, Parini R, Rigoldi M, Stella A.
“European Symposium on Lysosomal Storage Disorders”, London, November 21st-22nd 2014.
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Lectures
Academic lectures:
•

May 7th 2018. [Acute Kidney Injury in the Intensive Care Unit], in Italian. Elective course
“Dialysis”. School of Medicine and Surgery, Milano-Bicocca University, Monza, Italy.

•

April 11th 2017. [Acute Kidney Injury, Sepsis and Renal Replacement Therapy], in Italian.
Elective course “Dialysis”. School of Medicine and Surgery, Milano-Bicocca University,
Monza, Italy.

•

April 6th 2017. [Elements of Plasmapheresis and Vascular Access for Hemodialysis], in
Italian. Elective course “Dialysis”. School of Medicine and Surgery, Milano-Bicocca
University, Monza, Italy.

Contract lectures – Sponsored by Genzyme, a Sanofi Company.
•

June 12th-13th 2018. [The Role of High-Sensitivity Troponin T in Fabry Cardiomyopathy],
in Italian. “Fabry Excellence Meeting”, Naples, Italy.

•

May 23rd-24th 2017. [Fabry disease: how to predict renal outcomes], in Italian. “Master
School: advanced course on Fabry disease”, Monza, Italy.

•

February 9th-10th 2016. [The Role of High-Sensitivity Troponin T in Fabry
Cardiomyopathy], in Italian. “Fabry Excellence Meeting”, Baggiovara, Italy.

•

May 6th-7th 2015. [The role of the cardiologist: clinical cases], in Italian. “Master School:
advanced course on Fabry disease”, Monza, Italy.

•

September 18th-19th 2014. [The role of the cardiologist: clinical cases], in Italian. “Master
School: advanced course on Fabry disease”, Monza, Italy.

Clinical lectures:
•

July 7th 2015. [Use of Biofeedback Mechanisms in Hemodialysis], in Italian. Update
course for dialysis nurses. San Gerardo Hospital, Monza, Italy.

Online lectures:
•

2017. Salerno FR, Slessarev M. Authored informative Powerpoint slides and video
tutorials for cardiac ultrasound image acquisition and interpretation with the Echopac GE
software. (https://sites.google.com/scary/view/mcvaderlab/echo-tutorial)
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Editorial Activity
Review Editor for Frontiers in Medicine (2021 IF: 5.058), section Nephrology, since August
2022.

Peer Review Activity
Peer reviewer for the following Peer-Reviewed journals: Scientific Reports (2021 IF: 4.996),
Clinical Journal of the American Society of Nephrology (2021 IF: 10.671), Frontiers in Medicine
(2021 IF: 5.058), Frontiers in Neurology (2021 IF: 4.086), Hemodialysis International (2021 IF:
1.543), BMC Nephrology (2021 IF: 2.585).

Mentorship Activity
2018

Miss Martina Milani, medical student. MD dissertation: [Volume Depletion
Induced by Hemodialysis: a Model for the Echocardiographic Study of the
Complex Relationship Between Pump Function and Myocardial Function], in
Italian.

2017

Miss Veronica Evasi, medical student. MD dissertation: [Role of Cardiac
Biomarkers and Imaging Techniques for the Evaluation of Cardiac Involvement
in Patients Affected by Fabry Disease], in Italian.
Miss Francesca Pescatore, medical student. MD dissertation: [The Burden of
Childhood Abuse: Personality Disorders and Potential Psychiatric Perinatal
Relapses], in Italian.

2016

Miss Anna Calastri, medical student. MD dissertation: [Post-Tonsillectomy
Bleeding: Literature Review and Case Analysis], in Italian.

Volunteer Activity
April 2019 – February 2020: Chess Instructor at the Spriet Family Children's Library, London
Public Library, London, ON, Canada.
2016-2017: Chess Classes for Beginner Players London
Community Centre, London, ON, Canada.

Chess

Club,

Kiwanis

Seniors’

2003-2007: Summertime caregiver at a seaside residence for people with disabilities at the
UNITALSI Association, Borghetto Santo Spirito, Italy.
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